WHAT IS CLAIMED IS:

1. A compound of Formula (I):



(I)

or a pharmaceutically acceptable salt thereof, wherein

R^1 is hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, halogen, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, or –CN;

R^2 is hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} hydroxyalkyl, C_{1-6} aminoalkyl, C_{1-6} alkoxy, C_{2-6} alkoxyalkyl, halogen, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, -CN, -NO, -NO_2, -$C(O)R^{2a}$, -$C(O)OR^{2a}$, -$OC(O)R^{2a}$, -$C(O)N(R^{2a})(R^{2b})$, -$N(R^{2a})C(O)R^{2b}$, -$OC(O)N(R^{2a})(R^{2b})$, -$N(R^{2a})C(O)OR^{2b}$, -$C(=NR^{2a})N(R^{2b})(R^{2c})$, -$N(R^{2a})(R^{2b})$, -$N(R^{2a})N(R^{2b})(R^{2c})$, -$N(R^{2a})N=C(R^{2b})(OR^{2c})$, -$OR^{2a}$, -$SR^{2a}$, -$S(O)R^{2a}$, -$S(O)(NR^{2a})(R^{2b})$, -$S(NR^{2a})(NR^{2b})(R^{2c})$, -$S(O)_2R^{2a}$, -$S(O)_2N(R^{2a})(R^{2b})$, -$N(R^{2a})S(O)_2(R^{2b})$, -$P(R^{2a})(R^{2b})$, -$P(O)(R^{2a})(R^{2b})$, -$P(O)(OR^{2a})(R^{2b})$, -$P(O)(OR^{2a})(OR^{2b})$, C_{3-10} cycloalkyl, C_{1-6} alkyl-C_{3-10} cycloalkyl, C_{6-12} aryl, C_{1-6} alkyl-C_{6-12} aryl, heterocycloalkyl, C_{1-6} alkyl-(heterocycloalkyl), heteroaryl, or C_{1-6} alkyl-(heteroaryl), wherein each alkyl, alkenyl or alkynyl is independently optionally substituted with 1 to 3 R^{2d} groups, each cycloalkyl is optionally substituted with 1 to 3 R^{2e} groups, each aryl is optionally substituted with 1 to 3 R^{2f} groups, each heterocycloalkyl is optionally substituted with 1 to 3 R^{2g} groups, and each heteroaryl is optionally substituted with 1 to 3 R^{2h} groups;

each R^{2a}, R^{2b}, and R^{2c} is independently hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} hydroxyalkyl, C_{1-6} aminoalkyl, C_{2-6} alkoxyalkyl, C_{1-6} haloalkyl, C_{3-10} cycloalkyl, C_{1-6} alkyl-C_{3-10} cycloalkyl, C_{6-12} aryl, C_{1-6} alkyl-C_{6-12} aryl, heterocycloalkyl, C_{1-6} alkyl-(heterocycloalkyl), heteroaryl, or C_{1-6} alkyl-

(heteroaryl), wherein the aryl or heteroaryl is optionally substituted with 1 to 3 R^{2j};

alternatively, R^{2a}, R^{2b}, and R^{2c} when attached to the same atom can be combined with the atom to which they are attached to form a heterocycloalkyl;

each R^{2d} is independently –CN, -C(O)R^{2d1}, -C(O)OR^{2d1}, -OC(O)R^{2d1}, -C(O)N(R^{2d1})(R^{2d2}), -N(R^{2d1})C(O)R^{2d2}, -OC(O)N(R^{2d1})(R^{2d2}), -N(R^{2d1})C(O)OR^{2d2}, -N(R^{2d1})(R^{2d2}), =O, -OR^{2d1}, -SR^{2d1}, -S(O)R^{2d1}, -S(O)(NR^{2d1})(R^{2d2}), -S(O)$_2$$R^{2d1}$, -S(O)N($R^{2d1}$)($R^{2d2}$), -N($R^{2d1}$)S(O)$_2$$R^{2d2}$, C_{3-10} cycloalkyl, C_{1-6} alkyl-C_{3-10} cycloalkyl, C_{6-12} aryl, C_{1-6} alkyl-C_{6-12} aryl, heterocycloalkyl, C_{1-6} alkyl-(heterocycloalkyl), heteroaryl, or C_{1-6} alkyl-(heteroaryl);

each R^{2d1} and R^{2d2} is independently hydrogen, C_{1-6} alkyl, C_{1-6} hydroxyalkyl, C_{1-6} aminoalkyl, C_{2-6} alkoxyalkyl, or C_{1-6} haloalkyl;

each R^{2e}, R^{2f}, R^{2g}, and R^{2h} is independently hydrogen, C_{1-6} alkyl, C_{1-6} hydroxyalkyl, C_{1-6} aminoalkyl, C_{1-6} alkoxy, C_{2-6} alkoxyalkyl, halogen, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, -CN, or -OH;

each R^{2j} is independently C_{1-6} alkyl, C_{1-6} hydroxyalkyl, C_{1-6} aminoalkyl, C_{1-6} alkoxy, C_{2-6} alkoxyalkyl, halogen, C_{1-6} haloalkyl, or C_{1-6} haloalkoxy;

R^3 is hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} hydroxyalkyl, C_{1-6} aminoalkyl, C_{1-6} alkoxy, C_{2-6} alkoxyalkyl, halogen, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, -CN, -NO, -NO_2, -C(O)R^{3a}, -C(O)OR^{3a}, -OC(O)R^{3a}, -C(O)N(R^{3a})(R^{3b}), -N(R^{3a})C(O)R^{3b}, -OC(O)N(R^{3a})(R^{3b}), -N(R^{3a})C(O)OR^{3b}, -C(=NR^{3a})N(R^{3b})(R^{3c}), -N(R^{3a})(R^{3b}), -N(R^{3a})N(R^{3b})(R^{3c}), -N(R^{3a})N=C(R^{3b})(OR^{3c}), -OR^{3a}, -SR^{3a}, -S(O)R^{3a}, -S(O)(NR^{3a})(R^{3b}), -S(NR^{3a})(NR^{3b})(R^{3c}), -S(O)$_2$$R^{3a}$, -S(O)$_2$N($R^{3a}$)($R^{3b}$), -N($R^{3a}$)S(O)$_2$($R^{3b}$), -P($R^{3a}$)($R^{3b}$), -P(O)($R^{3a}$)($R^{3b}$), -P(O)(O$R^{3a}$)($R^{3b}$), -P(O)(O$R^{3a}$)(O$R^{3b}$), C_{3-10} cycloalkyl, C_{1-6} alkyl-C_{3-10} cycloalkyl, C_{6-12} aryl, C_{1-6} alkyl-C_{6-12} aryl, heterocycloalkyl, C_{1-6} alkyl-(heterocycloalkyl), heteroaryl, or C_{1-6} alkyl-(heteroaryl), wherein each alkenyl or alkynyl is independently optionally substituted with 1 to 3 R^{3d} groups, each cycloalkyl is optionally substituted with 1 to 3 R^{3e} groups, each aryl is optionally substituted with 1 to 3 R^{3f} groups, each heterocycloalkyl is optionally substituted with 1 to 3 R^{3g} groups, and each heteroaryl is optionally substituted with 1 to 3 R^{3h} groups;

each R^{3a}, R^{3b}, and R^{3c} is independently hydrogen, C_{1-6} alkyl, C_{1-6} hydroxyalkyl, C_{2-6} alkoxyalkyl, C_{1-6} haloalkyl, C_{3-10} cycloalkyl, C_{1-6} alkyl-C_{3-10} cycloalkyl, C_{6-12} aryl, C_{1-6} alkyl-C_{6-12} aryl, heterocycloalkyl, or heteroaryl;

alternatively, R^{3a}, R^{3b}, and R^{3c} when attached to the same atom can be combined with the atom to which they are attached to form a heterocycloalkyl;

each R^{3d} is independently -$N(R^{3d1})(R^{3d2})$, -OR^{3d1}, C_{3-10} cycloalkyl, C_{1-6} alkyl-C_{3-10} cycloalkyl, C_{6-12} aryl, C_{1-6} alkyl-C_{6-12} aryl, heterocycloalkyl, or heteroaryl;

each R^{3d1} and R^{3d2} is independently hydrogen, C_{1-6} alkyl, or –C(O)O-(C_{1-6} alkyl);

each R^{3e}, R^{3f}, R^{3g}, and R^{3h} is independently hydrogen, C_{1-6} alkyl, C_{1-6} alkoxy, halogen, C_{1-6} haloalkyl or C_{1-6} haloalkoxy;

R^4 is hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, halogen, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, or –CN;

R^5 is C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} hydroxyalkyl, C_{2-6} alkoxyalkyl, C_{1-6} haloalkyl, C_{3-10} cycloalkyl, C_{1-6} alkyl-C_{3-10} cycloalkyl, C_{6-12} aryl, C_{1-6} alkyl-C_{6-12} aryl, heterocycloalkyl, C_{1-6} alkyl-(heterocycloalkyl), heteroaryl, or C_{1-6} alkyl-(heteroaryl);

R^6 is C_{6-12} aryl or heteroaryl, wherein the aryl or heteroaryl are each optionally substituted with 1 to 3 R^{6a};

~~R^5 is hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} hydroxyalkyl, C_{2-6} alkoxyalkyl, C_{1-6} haloalkyl, C_{3-10} cycloalkyl, C_{1-6} alkyl-C_{3-10} cycloalkyl, C_{6-12} aryl, C_{1-6} alkyl-C_{6-12} aryl, heterocycloalkyl, C_{1-6} alkyl-(heterocycloalkyl), heteroaryl, or C_{1-6} alkyl-(heteroaryl), wherein the alkyl is optionally substituted with R^{5a};~~

~~R^{5a} is –$OSi(R^{5a1})(R^{5a2})(R^{5a3})$;~~

~~R^{5a1}, R^{5a2}, and R^{5a3} are each independently C_{1-6} alkyl; and~~

~~R^6 is C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, C_{6-12} aryl, or heteroaryl, wherein the aryl or heteroaryl are each optionally substituted with 1 to 3 R^{6a};~~

each R^{6a} is independently C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} hydroxyalkyl, C_{1-6} aminoalkyl, C_{1-6} alkoxy, C_{2-6} alkoxyalkyl, halogen, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, –CN, -NO_2, -$C(O)R^{6b}$, -$C(O)OR^{6b}$, -$OC(O)R^{6b}$, -$C(O)N(R^{6b})(R^{6c})$, -$N(R^{6b})C(O)R^{6c}$, -$C(=NR^{6b})N(R^{6c})(R^{6d})$, -$N(R^{6b})(R^{6c})$, -$OR^{6b}$, -$SR^{6b}$, -$S(O)R^{6b}$, -$S(O)_2R^{6b}$, -$S(NR^{6b})(NR^{6c})R^{6d}$, -$S(O)(NR^{6b})(R^{6c})$, -$S(O)_2N(R^{6b})(R^{6c})$, -

$N(R^{6b})S(O)_2(R^{6c})$, $-P(R^{6b})(R^{6c})$, $-P(O)(R^{6b})(R^{6c})$, $-P(O)(OR^{6b})(R^{6c})$, $-P(O)(OR^{6b})(OR^{6c})$, C_{3-10} cycloalkyl, C_{1-6} alkyl-C_{3-10} cycloalkyl, C_{6-12} aryl, C_{1-6} alkyl-C_{6-12} aryl, heterocycloalkyl, C_{1-6} alkyl-(heterocycloalkyl), heteroaryl, or C_{1-6} alkyl-(heteroaryl), wherein the cycloalkyl, aryl, heterocycloalkyl, or heteroaryl is each optionally substituted with 1 to 3 R^{6e}, the alkyl is optionally substituted with R^{6f}, and the alkynyl is optionally substituted with 1 to 4 R^{6j};

each R^{6b}, R^{6c} and R^{6d} is independently hydrogen, C_{1-6} alkyl, C_{1-6} hydroxyalkyl, C_{1-6} aminoalkyl, C_{2-6} alkoxyalkyl, C_{1-6} haloalkyl, C_{3-10} cycloalkyl, C_{1-6} alkyl-C_{3-10} cycloalkyl, C_{6-12} aryl, C_{1-6} alkyl-C_{6-12} aryl, heterocycloalkyl, C_{1-6} alkyl-(heterocycloalkyl), heteroaryl, or C_{1-6} alkyl-(heteroaryl), wherein the cycloalkyl, aryl, heterocycloalkyl, or heteroaryl is optionally substituted by 1 to 3 R^{6k};

each R^{6k} is independently C_{1-6} alkyl, C_{1-6} hydroxyalkyl, C_{1-6} aminoalkyl, C_{1-6} alkoxy, C_{2-6} alkoxyalkyl, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, C_{3-10} cycloalkyl, C_{1-6} alkyl-C_{3-10} cycloalkyl, heterocycloalkyl, or C_{1-6} alkyl-(heterocycloalkyl);

each R^{6e} is independently C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} hydroxyalkyl, C_{1-6} aminoalkyl, C_{1-6} alkoxy, C_{2-6} alkoxyalkyl, halogen, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, –CN, $-NO_2$, $-C(O)R^{6e1}$, $-C(O)OR^{6e1}$, $-OC(O)R^{6e1}$, $-C(O)N(R^{6e1})(R^{6e2})$, $-N(R^{6e1})C(O)R^{6e2}$, $-OC(O)N(R^{6e1})(R^{6e2})$, $-N(R^{6e1})C(O)OR^{6e2}$, $-C(=NR^{6e1})N(R^{6e2})(R^{6e3})$, $-N(R^{6e1})(R^{6e2})$, =O, $-OR^{6e1}$, $-SR^{6e1}$, $-S(O)R^{6e1}$, $-S(NR^{6e1})(NR^{6e2})$, $-S(O)(NR^{6e1})(R^{6e2})$, $-S(O)_2R^{6e1}$, $-S(O)_2N(R^{6e1})(R^{6e2})$, $-SF_5$, $-N(R^{6e1})S(O)_2(R^{6e2})$, $-P(R^{6e1})(R^{6e2})$, $-P(O)(R^{6e1})(R^{6e2})$, $-P(O)(OR^{6e1})(R^{6e2})$, $-P(O)(OR^{6e1})(OR^{6e2})$, $-Si(R^{6e1})(R^{6e2})(R^{6e3})$, C_{3-10} cycloalkyl, C_{1-6} alkyl-C_{3-10} cycloalkyl, C_{6-12} aryl, C_{1-6} alkyl-C_{6-12} aryl, heterocycloalkyl, C_{1-6} alkyl-heterocycloalkyl, heteroaryl, or C_{1-6} alkyl-heteroaryl, wherein the cycloalkyl, aryl, heterocycloalkyl, or heteroaryl is each optionally substituted with 1 to 3 R^{6h}, and the alkyl is optionally substituted with 1 to 3 R^{6m};

each R^{6e1}, R^{6e2}, and R^{6e3} is independently hydrogen, C_{1-6} alkyl, C_{1-6} hydroxyalkyl, C_{1-6} aminoalkyl, C_{1-6} alkoxyalkyl, C_{1-6} haloalkyl, C_{3-10} cycloalkyl, C_{1-6} alkyl-C_{3-10} cycloalkyl, C_{6-10} aryl, C_{1-6} alkyl-C_{6-10} aryl, heterocycloalkyl, C_{1-6} alkyl-(heterocycloalkyl), heteroaryl, or C_{1-6} alkyl-(heteroaryl), wherein the cycloalkyl, aryl, heterocycloalkyl, or heteroaryl is optionally substituted with 1 to 3 R^{6n};

each R^{6n} is C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} hydroxyalkyl, C_{1-6} aminoalkyl, C_{1-6} alkoxy, C_{2-6} alkoxyalkyl, halogen, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, -CN, -$C(O)R^{6n1}$, -$C(O)OR^{6n1}$, -$OC(O)R^{6n1}$, -$C(O)N(R^{6n1})(R^{6n2})$, -$N(R^{6n1})C(O)R^{6n2}$, -$OC(O)N(R^{6n1})(R^{6n2})$, -$N(R^{6n1})C(O)OR^{6n2}$, -$C(=NR^{6n1})N(R^{6n2})(R^{6n3})$, -$N(R^{6n1})(R^{6n2})$, =O, –OH, -$SR^{6n1}$, -$S(O)R^{6n1}$, -$S(NR^{6n1})(NR^{6n2})R^{6n3}$, -$S(O)(NR^{6n1})(R^{6n2})$, -$S(O)_2R^{6n1}$, -$S(O)_2N(R^{6n1})(R^{6n2})$, or -$N(R^{6n1})S(O)_2(R^{6n2})$;

each R^{6n1}, R^{6n2} and R^{6n3} is independently hydrogen, C_{1-6} alkyl, C_{1-6} hydroxyalkyl, C_{1-6} aminoalkyl, C_{2-6} alkoxyalkyl, C_{1-6} haloalkyl, C_{3-10} cycloalkyl, C_{1-6} alkyl-C_{3-10} cycloalkyl, C_{6-10} aryl, C_{1-6} alkyl-C_{6-10} aryl, heterocycloalkyl, C_{1-6} alkyl-(heterocycloalkyl), heteroaryl, or C_{1-6} alkyl-(heteroaryl);

each R^{6h} is independently C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} hydroxyalkyl, C_{1-6} aminoalkyl, C_{1-6} alkoxy, C_{2-6} alkoxyalkyl, halogen, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, -CN, -$C(O)R^{6h1}$, -$C(O)OR^{6h1}$, -$OC(O)R^{6h1}$, -$C(O)N(R^{6h1})(R^{6h2})$, -$N(R^{6h1})C(O)R^{6h2}$, -$OC(O)N(R^{6h1})(R^{6h2})$, -$N(R^{6h1})C(O)OR^{6h2}$, -$C(=NR^{6h1})N(R^{6h2})(R^{6h3})$, -$N(R^{6h1})(R^{6h2})$, =O, –OH, -$SR^{6h1}$, -$S(O)R^{6h1}$, -$S(NR^{6h1})(NR^{6h2})R^{6h3}$, -$S(O)(NR^{6h1})(R^{6h2})$, -$S(O)_2R^{6h1}$, -$S(O)_2N(R^{6h1})(R^{6h2})$, -$N(R^{6h1})S(O)_2(R^{6h2})$, C_{3-10} cycloalkyl, C_{1-6} alkyl-C_{3-10} cycloalkyl, heterocycloalkyl, or C_{1-6} alkyl-(heterocycloalkyl);

each R^{6h1}, R^{6h2}, and R^{6h3} is independently hydrogen, C_{1-6} alkyl, C_{1-6} hydroxyalkyl, C_{1-6} aminoalkyl, C_{2-6} alkoxyalkyl, C_{1-6} haloalkyl, C_{3-10} cycloalkyl, C_{1-6} alkyl-C_{3-10} cycloalkyl, C_{6-10} aryl, C_{1-6} alkyl-C_{6-10} aryl, heterocycloalkyl, C_{1-6} alkyl-(heterocycloalkyl), heteroaryl, or C_{1-6} alkyl-(heteroaryl);

each R^{6m} is independently halogen, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, -CN, -$C(O)R^{6m1}$, -$C(O)OR^{6m1}$, -$OC(O)R^{6m1}$, -$C(O)N(R^{6m1})(R^{6m2})$, -$N(R^{6m3})C(O)R^{6m2}$, -$OC(O)N(R^{6m1})(R^{6m2})$, -$N(R^{6m1})C(O)OR^{6m2}$, -$C(=NR^{6m3})N(R^{6m1})(R^{6m2})$, -$N(R^{6m1})(R^{6m2})$, =O, –OH, -$SR^{6m1}$, -$S(O)R^{6m1}$, -$S(NR^{6m1})(NR^{6m2})R^{6m3}$, -$S(O)(NR^{6m1})(R^{6m2})$, -$S(O)_2R^{6m1}$, -$S(O)_2N(R^{6m1})(R^{6m2})$, or -$N(R^{6m3})S(O)_2(R^{6m2})$;

each R^{6m1}, R^{6m2}, and R^{6m3} is independently hydrogen, C_{1-6} alkyl, C_{1-6} hydroxyalkyl, C_{1-6} aminoalkyl, C_{2-6} alkoxyalkyl, C_{1-6} haloalkyl, C_{3-10} cycloalkyl, C_{1-6} alkyl-C_{3-10} cycloalkyl, C_{6-10} aryl, C_{1-6} alkyl-C_{6-10} aryl, heterocycloalkyl, C_{1-6} alkyl-(heterocycloalkyl), heteroaryl, or C_{1-6} alkyl-(heteroaryl);

R^{6f} is –OSi(R^{6f1})(R^{6f2})(R^{6f3});

R^{6f1}, R^{6f2}, and R^{6f3} are each independently C_{1-6} alkyl;

each R^{6j} is independently C_{2-6} alkoxyalkyl, halogen, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, -CN, -C(O)R^{6j1}, -C(O)OR^{6j1}, -OC(O)R^{6j1}, -C(O)N(R^{6j1})(R^{6j2}), -N(R^{6j3})C(O)R^{6j2}, -OC(O)N(R^{6j1})(R^{6j2}), -N(R^{6j1})C(O)OR^{6j2}, -C(=NR^{6j3})N(R^{6j1})(R^{6j2}), -N(R^{6j1})(R^{6j2}), =O, –OR^{6j1}, -SR^{6j1}, -S(O)R^{6j1}, -S(NR^{6j1})(NR^{6j2}), -S(NR^{6j1})(NR^{6j2})R^{6j3}, -S(O)(NR^{6j1})(R^{6j2}), -S(O)$_2$$R^{6j1}$, -S(O)$_2$N($R^{6j1}$)($R^{6j2}$), -N($R^{6j1}$)S(O)$_2$($R^{6j2}$), -Si($R^{6j1}$)($R^{6j2}$)($R^{6j3}$), C_{3-10} cycloalkyl, C_{6-12} aryl, heterocycloalkyl, or heteroaryl, wherein the cycloalkyl, aryl, heterocycloalkyl, or heteroaryl is optionally substituted with 1 to 3 R^{6p};

each R^{6j1}, R^{6j2}, and R^{6j3} is independently hydrogen, C_{1-6} alkyl, C_{1-6} hydroxyalkyl, C_{1-6} aminoalkyl, C_{2-6} alkoxyalkyl, C_{1-6} haloalkyl, C_{3-10} cycloalkyl, C_{1-6} alkyl-C_{3-10} cycloalkyl, C_{6-10} aryl, C_{1-6} alkyl-C_{6-10} aryl, heterocycloalkyl, C_{1-6} alkyl-(heterocycloalkyl), heteroaryl, or C_{1-6} alkyl-(heteroaryl);

each R^{6p} is independently C_{1-6} alkyl, C_{1-6} hydroxyalkyl, C_{1-6} aminoalkyl, C_{1-6} alkoxy, C_{2-6} alkoxyalkyl, halogen, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, -CN, -C(O)R^{6p1}, -C(O)OR^{6p1}, -OC(O)R^{6p1}, -C(O)N(R^{6p1})(R^{6p2}), -N(R^{6p1})C(O)R^{6p2}, -OC(O)N(R^{6p1})(R^{6p2}), -N(R^{6p1})C(O)OR^{6p2}, -C(=NR^{6p3})N(R^{6p1})(R^{6p2}), -N(R^{6p1})(R^{6p2}), =O, -OH, -SR^{6p1}, -S(O)R^{6p1}, -S(NR^{6p1})(NR^{6p2})R^{6p3}, -S(O)(NR^{6p1})(R^{6p2}), -S(O)$_2$$R^{6p1}$, -S(O)$_2$N($R^{6p1}$)($R^{6p2}$), or -N($R^{6p1}$)S(O)$_2$($R^{6p2}$);

each R^{6p1}, R^{6p2}, and R^{6p3} is independently hydrogen, C_{1-6} alkyl, C_{1-6} hydroxyalkyl, C_{1-6} aminoalkyl, C_{2-6} alkoxyalkyl, C_{1-6} haloalkyl, C_{3-10} cycloalkyl, C_{1-6} alkyl-C_{3-10} cycloalkyl, C_{6-10} aryl, C_{1-6} alkyl-C_{6-10} aryl, heterocycloalkyl, C_{1-6} alkyl-(heterocycloalkyl), heteroaryl, or C_{1-6} alkyl-(heteroaryl);

or R^5 and one R^{6a} together with the atoms to which they are attached form a heterocycloalkyl, optionally substituted with 1 to 3 R^{6g};

each R^{6g} is independently C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} hydroxyalkyl, C_{1-6} aminoalkyl, C_{2-6} alkoxyalkyl, halogen, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, or –CN;

R^7 is hydrogen, C_{1-6} alkyl, C_{1-6} hydroxyalkyl, C_{1-6} aminoalkyl, C_{1-6} alkoxy, C_{2-6} alkoxyalkyl, C_{1-6} alkylthio, halogen, C_{1-6} haloalkyl, –CN,–OH, -NH_2, C_{3-10}

cycloalkyl, C_{1-6} alkyl-C_{3-10} cycloalkyl, heterocycloalkyl, or C_{1-6} alkyl-(heterocycloalkyl);

each heterocycloalkyl is a 3 to 20 membered ring having 1 to 4 heteroatoms each independently N, O or S; and

each heteroaryl is a 5 to 18 membered ring having 1 to 4 heteroatoms each independently N, O or S.;

~~provided that R^5 and R^6 are not both C_{1-4} alkyl; and~~

~~when R^5 is hydrogen, R^6 is not isopropyl or phenyl substituted with 2-Me.~~

~~2. A compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein~~

~~R^1 is hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, halogen, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, or –CN;~~

~~R^2 is hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} hydroxyalkyl, C_{1-6} alkoxy, C_{2-6} alkoxyalkyl, halogen, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, –CN, –NO, –NO_2, –$C(O)R^{2a}$, –$C(O)OR^{2a}$, –$OC(O)R^{2a}$, –$C(O)N(R^{2a})(R^{2b})$, –$N(R^{2a})C(O)R^{2b}$, –$OC(O)N(R^{2a})(R^{2b})$, –$N(R^{2a})C(O)OR^{2b}$, –$C(=NR^{2a})N(R^{2b})(R^{2e})$, –$N(R^{2a})(R^{2b})$, –$OR^{2a}$, –$SR^{2a}$, –$S(O)R^{2a}$, –$S(O)_2R^{2a}$, –$S(O)_2N(R^{2a})(R^{2b})$, –$N(R^{2a})S(O)_2(R^{2b})$, –$P(O)(R^{2a})(R^{2b})$, –$P(O)(OR^{2a})(R^{2b})$, –$P(O)(OR^{2a})(OR^{2b})$, C_{3-10} cycloalkyl, C_{1-6} alkyl-C_{3-10} cycloalkyl, C_{6-12} aryl, C_{1-6} alkyl-C_{6-12} aryl, heterocycloalkyl, or heteroaryl, wherein each alkenyl or alkynyl is independently optionally substituted with 1 to 3 R^{2d} groups, each cycloalkyl is optionally substituted with 1 to 3 R^{2e} groups, each aryl is optionally substituted with 1 to 3 R^{2f} groups, each heterocycloalkyl is optionally substituted with 1 to 3 R^{2g} groups, and each heteroaryl is optionally substituted with 1 to 3 R^{2h} groups;~~

~~each R^{2a}, R^{2b}, and R^{2e} is independently hydrogen, C_{1-6} alkyl, C_{1-6} hydroxyalkyl, C_{2-6} alkoxyalkyl, C_{1-6} haloalkyl, C_{3-10} cycloalkyl, C_{1-6} alkyl-C_{3-10} cycloalkyl, C_{6-12} aryl, C_{1-6} alkyl-C_{6-12} aryl, heterocycloalkyl, or heteroaryl;~~

~~alternatively, R^{2a}, R^{2b}, and R^{2e} when attached to the same atom can be combined with the atom to which they are attached to form a heterocycloalkyl;~~

each R^{2d} is independently -$N(R^{2d1})(R^{2d2})$, -OR^{2d1}, C_{3-10} cycloalkyl, C_{1-6} alkyl-C_{3-10} cycloalkyl, C_{6-12} aryl, C_{1-6} alkyl-C_{6-12} aryl, heterocycloalkyl, or heteroaryl;

each R^{2d1} and R^{2d2} is independently hydrogen, C_{1-6} alkyl, or -C(O)O-(C_{1-6} alkyl);

each R^{2e}, R^{2f}, R^{2g}, and R^{2h} is independently hydrogen, C_{1-6} alkyl, C_{1-6} alkoxy, halogen, C_{1-6} haloalkyl or C_{1-6} haloalkoxy;

R^3 is hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} hydroxyalkyl, C_{1-6} alkoxy, C_{2-6} alkoxyalkyl, halogen, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, -CN, -NO, -NO_2, -$C(O)R^{3a}$, -$C(O)OR^{3a}$, -$OC(O)R^{3a}$, -$C(O)N(R^{3a})(R^{3b})$, -$N(R^{3a})C(O)R^{3b}$, -$OC(O)N(R^{3a})(R^{3b})$, -$N(R^{3a})C(O)OR^{3b}$, -$C(=NR^{3a})N(R^{3b})(R^{3e})$, -$N(R^{3a})(R^{3b})$, -$OR^{3a}$, -$SR^{3a}$, -$S(O)R^{3a}$, -$S(O)_2R^{3a}$, -$S(O)_2N(R^{3a})(R^{3b})$, -$N(R^{3a})S(O)_2(R^{3b})$, -$P(O)(R^{3a})(R^{3b})$, -$P(O)(OR^{3a})(R^{3b})$, -$P(O)(OR^{3a})(OR^{3b})$, C_{3-10} cycloalkyl, C_{1-6} alkyl-C_{3-10} cycloalkyl, C_{6-12} aryl, C_{1-6} alkyl-C_{6-12} aryl, heterocycloalkyl, or heteroaryl, wherein each alkenyl or alkynyl is independently optionally substituted with 1 to 3 R^{3d} groups, each cycloalkyl is optionally substituted with 1 to 3 R^{3e} groups, each aryl is optionally substituted with 1 to 3 R^{3f} groups, each heterocycloalkyl is optionally substituted with 1 to 3 R^{3g} groups, and each heteroaryl is optionally substituted with 1 to 3 R^{3h} groups;

each R^{3a}, R^{3b}, and R^{3e} is independently hydrogen, C_{1-6} alkyl, C_{1-6} hydroxyalkyl, C_{2-6} alkoxyalkyl, C_{1-6} haloalkyl, C_{3-10} cycloalkyl, C_{1-6} alkyl-C_{3-10} cycloalkyl, C_{6-12} aryl, C_{1-6} alkyl-C_{6-12} aryl, heterocycloalkyl, or heteroaryl;

alternatively, R^{3a}, R^{3b}, and R^{3e} when attached to the same atom can be combined with the atom to which they are attached to form a heterocycloalkyl;

each R^{3d} is independently -$N(R^{3d1})(R^{3d2})$, -OR^{3d1}, C_{3-10} cycloalkyl, C_{1-6} alkyl-C_{3-10} cycloalkyl, C_{6-12} aryl, C_{1-6} alkyl-C_{6-12} aryl, heterocycloalkyl, or heteroaryl;

each R^{3d1} and R^{3d2} is independently hydrogen, C_{1-6} alkyl, or -C(O)O-(C_{1-6} alkyl);

each R^{3e}, R^{3f}, R^{3g}, and R^{3h} is independently hydrogen, C_{1-6} alkyl, C_{1-6} alkoxy, halogen, C_{1-6} haloalkyl or C_{1-6} haloalkoxy;

R^4 is hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, halogen, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, or -CN;

R^5 is hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} hydroxyalkyl, C_{2-6} alkoxyalkyl, C_{1-6} haloalkyl, C_{3-10} cycloalkyl, C_{1-6} alkyl-C_{3-10} cycloalkyl, C_{6-12} aryl, C_{1-6} alkyl-

C_{6-12} aryl, heterocycloalkyl, C_{1-6} alkyl-(heterocycloalkyl), heteroaryl, or C_{1-6} alkyl-(heteroaryl), wherein the alkyl is optionally substituted with R^{5a};

R^{5a} is $-OSi(R^{5a1})(R^{5a2})(R^{5a3})$;

R^{5a1}, R^{5a2}, and R^{5a3} are each independently C_{1-6} alkyl; and

R^{6} is C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, C_{6-12} aryl, or heteroaryl, wherein the aryl or heteroaryl are each optionally substituted with 1 to 3 R^{6a};

each R^{6a} is independently C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} hydroxyalkyl, C_{1-6} alkoxy, C_{2-6} alkoxyalkyl, halogen, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, $-CN$, $-NO_2$, $-C(O)R^{6b}$, $-C(O)OR^{6b}$, $-OC(O)R^{6b}$, $-C(O)N(R^{6b})(R^{6e})$, $-N(R^{6b})C(O)R^{6e}$, $-C(=NR^{6b})N(R^{6e})(R^{6d})$, $-N(R^{6b})(R^{6e})$, $-OR^{6b}$, $-SR^{6b}$, $-S(O)R^{6b}$, $-S(O)_2R^{6b}$, $-S(O)_2N(R^{6b})(R^{6e})$, $-N(R^{6b})S(O)_2(R^{6e})$, C_{3-10} cycloalkyl, C_{6-12} aryl, heterocycloalkyl, or heteroaryl, wherein the cycloalkyl, aryl, heterocycloalkyl, or heteroaryl is each optionally substituted with 1 to 3 R^{6e}, and the alkyl is optionally substituted with R^{6f};

or R^{5} and one R^{6a} together with the atoms to which they are attached form a heterocycloalkyl, optionally substituted with 1 to 3 R^{6g};

each R^{6b}, R^{6e} and R^{6d} is independently hydrogen, C_{1-6} alkyl, C_{1-6} hydroxyalkyl, C_{2-6} alkoxyalkyl, C_{1-6} haloalkyl, C_{3-10} cycloalkyl, C_{1-6} alkyl-C_{3-10} cycloalkyl, C_{6-12} aryl, C_{1-6} alkyl-C_{6-12} aryl, heterocycloalkyl, or heteroaryl;

each R^{6e} is independently C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} hydroxyalkyl, C_{1-6} alkoxy, C_{2-6} alkoxyalkyl, halogen, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, $-CN$, $-NO_2$, $-C(O)R^{6e1}$, $-C(O)OR^{6e1}$, $-OC(O)R^{6e1}$, $-C(O)N(R^{6e1})(R^{6e2})$, $-N(R^{6e1})C(O)R^{6e2}$, $-C(=NR^{6e1})N(R^{6e2})(R^{6e3})$, $-N(R^{6e1})(R^{6e2})$, $-OR^{6e1}$, $-SR^{6e1}$, $-S(O)R^{6e1}$, $-S(O)_2R^{6e1}$, $-S(O)_2N(R^{6e1})(R^{6e2})$, $-N(R^{6e1})S(O)_2(R^{6e2})$, C_{3-10} cycloalkyl, C_{6-12} aryl, heterocycloalkyl, or heteroaryl, wherein the cycloalkyl, aryl, heterocycloalkyl, or heteroaryl is each optionally substituted with 1 to 3 R^{6h};

each R^{6e1}, R^{6e2}, and R^{6e3} is independently hydrogen or C_{1-6} alkyl;

R^{6f} is $-OSi(R^{6f1})(R^{6f2})(R^{6f3})$;

R^{6f1}, R^{6f2}, and R^{6f3} are each independently C_{1-6} alkyl;

each R^{6g} is independently C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, halogen, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, or $-CN$;

~~each R^{6h} is independently C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, halogen, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, $-C(O)R^{6h1}$, $-C(O)OR^{6h1}$, $-OC(O)R^{6h1}$, $-C(O)N(R^{6h1})(R^{6h2})$, $-N(R^{6h1})C(O)R^{6h2}$, $-C(=NR^{6h1})N(R^{6h2})(R^{6h3})$, $-N(R^{6h1})(R^{6h2})$, —OH, $-SR^{6h1}$, $-S(O)R^{6h1}$, $-S(O)_2R^{6h1}$, $-S(O)_2N(R^{6h1})(R^{6h2})$, or $-N(R^{6h1})S(O)_2(R^{6h2})$;~~

~~each R^{6h1}, R^{6h2}, and R^{6h3} is independently hydrogen or C_{1-6} alkyl;~~

~~R^7 is hydrogen, C_{1-6} alkyl, halogen, C_{1-6} haloalkyl, —CN, or —OH;~~

~~each heterocycloalkyl is a 3-to-10 membered ring having 1-to-4 heteroatoms each independently N, O or S; and~~

~~each heteroaryl is a 5-to-10 membered ring having 1-to-4 heteroatoms each independently N, O or S;~~

~~provided that R^5 and R^6 are not both C_{1-4} alkyl; and~~

~~when R^5 is hydrogen, R^6 is not isopropyl or phenyl substituted with 2-Me.~~

~~3. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein~~

~~R^5 is C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} hydroxyalkyl, C_{2-6} alkoxyalkyl, C_{1-6} haloalkyl, C_{3-10} cycloalkyl, C_{1-6} alkyl-C_{3-10} cycloalkyl, C_{6-12} aryl, C_{1-6} alkyl-C_{6-12} aryl, heterocycloalkyl, C_{1-6} alkyl-(heterocycloalkyl), heteroaryl, or C_{1-6} alkyl-(heteroaryl), wherein the alkyl is optionally substituted with R^{5a}; and~~

~~R^6 is C_{6-12} aryl or heteroaryl, wherein the aryl or heteroaryl are each optionally substituted with 1 to 3 R^{6a};~~

~~or R^5 and R^{6a} together with the atoms to which they are attached form a heterocycloalkyl, optionally substituted with 1 to 3 R^{6g}.~~

~~4. The compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein R^1 is hydrogen, C_{1-6} alkyl, C_{1-6} alkoxy, halogen, C_{1-6} haloalkyl, or —CN.~~

~~5~~2. The compound of ~~any one of~~ claims ~~1 to 4~~, or a pharmaceutically acceptable salt thereof, wherein R^1 is hydrogen, C_{1-3} alkyl, C_{1-3} alkoxy, or halogen.

6. The compound of any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, wherein R^1 is hydrogen, Me, -OMe, F, or Cl.

7. The compound of any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein R^1 is hydrogen.

8. The compound of any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein

R^2 is hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} hydroxyalkyl, C_{1-6} alkoxy, C_{2-6} alkoxyalkyl, halogen, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, -CN, -NO, $-NO_2$, $-C(O)R^{2a}$, $-C(O)OR^{2a}$, $-OC(O)R^{2a}$, $-C(O)N(R^{2a})(R^{2b})$, $-N(R^{2a})C(O)R^{2b}$, $-OC(O)N(R^{2a})(R^{2b})$, $-N(R^{2a})C(O)OR^{2b}$, $-N(R^{2a})(R^{2b})$, $-OR^{2a}$, $-S(O)_2N(R^{2a})(R^{2b})$, $-N(R^{2a})S(O)_2(R^{2b})$, C_{3-10} cycloalkyl, C_{1-6} alkyl-C_{3-10} cycloalkyl, C_{6-12} aryl, C_{1-6} alkyl-C_{6-12} aryl, a 3 to 8 membered heterocycloalkyl ring having 1 to 3 heteroatoms each independently N, O, or S, or a 5 to 10 membered heteroaryl ring having 1 to 3 heteroatoms each independently N, O, or S, wherein each alkenyl or alkynyl is independently optionally substituted with 1 to 3 R^{2d} groups, and each aryl is optionally substituted with 1 to 3 R^{2f} groups;

each R^{2a} and R^{2b} is independently hydrogen, C_{1-6} alkyl, C_{1-6} hydroxyalkyl, C_{2-6} alkoxyalkyl, or C_{1-6} haloalkyl;

each R^{2d} is independently $-N(R^{2d1})(R^{2d2})$, $-OR^{2d1}$, C_{3-10} cycloalkyl, C_{1-6} alkyl-C_{3-10} cycloalkyl, C_{6-12} aryl, C_{1-6} alkyl-C_{6-12} aryl;

each R^{2d1} and R^{2d2} is independently hydrogen, C_{1-6} alkyl, or $-C(O)O-(C_{1-6}$ alkyl); and

each R^{2f} is independently hydrogen, C_{1-6} alkyl, C_{1-6} alkoxy, or halogen.

9. The compound of any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, wherein

R^2 is hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} hydroxyalkyl, C_{1-6} alkoxy, C_{2-6} alkoxyalkyl, halogen, C_{1-6} haloalkyl, -CN, -NO, $-NO_2$, $-C(O)R^{2a}$, $-C(O)OR^{2a}$, $-N(R^{2a})C(O)R^{2b}$, $-N(R^{2a})(R^{2b})$, $-OR^{2a}$, $-N(R^{2a})S(O)_2(R^{2b})$, C_{3-10} cycloalkyl, C_{6-10} aryl, a 5 to 8 membered

~~heterocycloalkyl ring having 1 to 2 heteroatoms each independently N, O, or S, or a 5 to 6 membered heteroaryl ring having 1 to 3 heteroatoms each independently N, O, or S, wherein each alkenyl or alkynyl is independently optionally substituted with 1 to 3 R^{2d} groups, and each aryl is optionally substituted with 1 to 3 R^{2f} groups;~~

~~each R^{2a} and R^{2b} is independently hydrogen, C_{1-6} alkyl, C_{1-6} hydroxyalkyl, or C_{2-6} alkoxyalkyl;~~

~~each R^{2d} is independently -$N(R^{2d1})(R^{2d2})$, -OR^{2d1}, C_{3-10} cycloalkyl, or C_{6-12} aryl;~~

~~each R^{2d1} and R^{2d2} is independently hydrogen, C_{1-4} alkyl, or –C(O)O-(C_{1-4} alkyl); and~~

~~each R^{2f} is independently C_{1-6} alkoxy or halogen.~~

~~10~~3. The compound of any one of claims 1 ~~to 9~~and 2, or a pharmaceutically acceptable salt thereof, wherein

R^2 is hydrogen, C_{1-3} alkyl, C_{2-3} alkenyl, C_{2-6} alkynyl, C_{1-3} hydroxyalkyl, C_{1-3} alkoxy, C_{2-3} alkoxyalkyl, halogen, C_{1-3} haloalkyl, -CN, -NO, -NO_2, -$C(O)R^{2a}$, -$C(O)OR^{2a}$, -$N(R^{2a})C(O)R^{2b}$, -$N(R^{2a})(R^{2b})$, -$N(R^{2a})S(O)_2(R^{2b})$, C_{3-6} cycloalkyl, phenyl, 5 to 6 membered heterocycloalkyl ring having 1 to 2 heteroatoms each independently N or O, or a 5 to 6 membered heteroaryl ring having 1 to 2 heteroatoms each independently N, O, or S, wherein each alkenyl or alkynyl is independently optionally substituted with 1 R^{2d} group, and each phenyl is optionally substituted with 1 R^{2f} group;

each R^{2a} and R^{2b} is independently hydrogen, C_{1-3} alkyl, C_{1-3} hydroxyalkyl, or C_{2-3} alkoxyalkyl;

each R^{2d} is independently -$N(R^{2d1})(R^{2d2})$, -OR^{2d1}, C_{3-8} cycloalkyl, or phenyl;

each R^{2d1} and R^{2d2} is independently hydrogen or –C(O)O-(C_{1-4} alkyl); and

each R^{2f} is independently C_{1-3} alkoxy or halogen.

~~11. The compound of any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, wherein~~

~~R^2 is hydrogen, Me, Et, iPr, -CH=CH_2, -CH=CHMe, -C(Me)=CH_2, -CMe=CHMe, -CH=$C(Me)_2$, -CH=CHEt, -C≡CH, -C≡C-Me, -C≡C-Et, -C≡C-tBu, -C≡C-CH_2OH, -C≡C-CMe_2(OH), -C≡C-CH_2NH_2, -C≡C-CH_2NHC(O)OtBu, -C≡C-~~

~~$CMe_2(SO_2Me)$, $-CH_2OH$, $-CH_2CH_2CH_2OH$, $-CH(OH)CH_2CH_3$, -OMe, -OEt, $-OCH_2CH=CH_2$, $-CH_2OMe$, $-CH_2NHMe$, $-CH_2NMe_2$, $-CH_2CH_2COOEt$, F, Cl, Br, I, $-CF_3$, -CN, -NO, $-NO_2$, -C(O)H, -COOH, -COOMe, -NHCOMe, $-NH_2$, -NHMe, $-NMe_2$, $-NHCH_2CH_2OH$, $-NHCH_2CH_2OMe$, $-NHSO_2Me$, -OH, -NH-N=CH-OEt, $-NH_2$-NH_2, SMe, SO_2Me, cyclopropyl,~~



~~12. The compound of any one of claims 1 to 11, or a pharmaceutically acceptable salt thereof, wherein~~

~~R^3 is hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} hydroxyalkyl, C_{1-6} alkoxy, C_{2-6} alkoxyalkyl, halogen, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, -CN, -NO, $-NO_2$, $-C(O)R^{3a}$, $-C(O)OR^{3a}$, $-OC(O)R^{3a}$, $-C(O)N(R^{3a})(R^{3b})$, $-N(R^{3a})C(O)R^{3b}$, $-OC(O)N(R^{3a})(R^{3b})$, $-N(R^{3a})C(O)OR^{3b}$, $-N(R^{3a})(R^{3b})$, $-OR^{3a}$, $-S(O)_2N(R^{3a})(R^{3b})$, $-N(R^{3a})S(O)_2(R^{3b})$, C_{3-10} cycloalkyl, C_{1-6} alkyl-C_{3-10} cycloalkyl, C_{6-12} aryl, C_{1-6} alkyl-C_{6-12} aryl, a 3 to 8 membered heterocycloalkyl ring having 1 to 3 heteroatoms each independently N, O, or S, or a 5 to 10 membered heteroaryl ring having 1 to 3 heteroatoms each independently N, O, or S, wherein each alkenyl or alkynyl is independently optionally~~

substituted with 1 to 3 R^{3d} groups, and each aryl is optionally substituted with 1 to 3 R^{3f} groups;

each R^{3a} and R^{3b} is independently hydrogen, C_{1-6} alkyl, C_{1-6} hydroxyalkyl, or C_{2-6} alkoxyalkyl;

each R^{3d} is independently $-N(R^{3d1})(R^{3d2})$, $-OR^{3d1}$, C_{3-10} cycloalkyl, or C_{6-12} aryl;

each R^{3d1} and R^{3d2} is independently hydrogen, C_{1-4} alkyl, or $-C(O)O-(C_{1-4}$ alkyl); and

each R^{3f} is independently C_{1-6} alkoxy or halogen.

13. The compound of any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, wherein

R^3 is hydrogen, C_{1-6} alkyl, C_{1-6} hydroxyalkyl, C_{1-6} alkoxy, C_{2-6} alkoxyalkyl, halogen, C_{1-6} haloalkyl, $-CN$, $-NO_2$, $-C(O)OR^{3a}$, $-C(O)N(R^{3a})(R^{3b})$, $-N(R^{3a})(R^{3b})$, $-N(R^{3a})S(O)_2(R^{3b})$, or a 5 to 6 membered heteroaryl ring having 1 to 3 heteroatoms each independently N, O, or S; and

each R^{3a} and R^{3b} is independently hydrogen or C_{1-6} alkyl.

14. The compound of any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, wherein

R^3 is hydrogen, C_{1-3} alkyl, C_{1-3} hydroxyalkyl, C_{1-3} alkoxy, C_{2-3} alkoxyalkyl, halogen, C_{1-3} haloalkyl, $-CN$, $-NO_2$, $-C(O)OR^{3a}$, $-C(O)N(R^{3a})(R^{3b})$, $-N(R^{3a})(R^{3b})$, $-N(R^{3a})S(O)_2(R^{3b})$, or a 5 to 6 membered heteroaryl ring having 1 or 2 heteroatoms each N; and

each R^{3a} and R^{3b} is independently hydrogen or C_{1-3} alkyl.

15. The compound of any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof, wherein

R^3 is hydrogen, Me, Et, $-CH_2OH$, $-OMe$, $-CH_2OMe$, F, Cl, Br, $-CF_3$, $-CN$, $-NO_2$, $-COOMe$, $-CONH_2$, $-NH_2$, $-NHSO_2Me$, or



~~16. The compound of any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, wherein~~

~~R^3 is hydrogen, C_{1-6} alkyl, C_{1-6} hydroxyalkyl, C_{1-6} alkoxy, C_{2-6} alkoxyalkyl, halogen, -CN, $-NO_2$, $-C(O)OR^{3a}$, $-C(O)N(R^{3a})(R^{3b})$, $-N(R^{3a})(R^{3b})$, $-N(R^{3a})S(O)_2(R^{3b})$, or a 5 to 6 membered heteroaryl ring having 1 to 3 heteroatoms each independently N, O, or S; and~~

~~each R^{3a} and R^{3b} is independently hydrogen or C_{1-6} alkyl.~~

~~17. The compound of any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, wherein~~

~~R^3 is hydrogen, C_{1-3} alkyl, C_{1-3} hydroxyalkyl, C_{1-3} alkoxy, C_{2-3} alkoxyalkyl, halogen, -CN, $-NO_2$, $-C(O)OR^{3a}$, $-C(O)N(R^{3a})(R^{3b})$, $-N(R^{3a})(R^{3b})$, $-N(R^{3a})S(O)_2(R^{3b})$, or a 5 to 6 membered heteroaryl ring having 1 or 2 heteroatoms each N; and~~

~~each R^{3a} and R^{3b} is independently hydrogen or C_{1-3} alkyl.~~

~~18~~4. The compound of any one of claims 1 to ~~17~~3, or a pharmaceutically acceptable salt thereof, wherein

R^3 is hydrogen, Me, Et, $-CH_2OH$, -OMe, $-CH_2OMe$, F, Cl, Br, -CN, $-NO_2$, -COOMe, $-CONH_2$, $-NH_2$, $-NHSO_2Me$, or



.

~~19. The compound of any one of claims 1 to 18, or a pharmaceutically acceptable salt thereof, wherein R^4 is hydrogen, C_{1-6} alkyl, C_{1-6} alkoxy, halogen, C_{1-6} haloalkyl, or CN.~~

~~20~~5. The compound of any one of claims 1 to ~~19~~4, or a pharmaceutically acceptable salt thereof, wherein R^4 is hydrogen, C_{1-6} alkyl, or halogen.

~~21. The compound of any one of claims 1 to 20, or a pharmaceutically acceptable salt thereof, wherein R^4 is hydrogen, Me, F, Cl, or Br.~~

22. The compound of any one of claims 1 to 21, or a pharmaceutically acceptable salt thereof, wherein R^4 is hydrogen.

23. The compound of any one of claims 1 to 22, or a pharmaceutically acceptable salt thereof, wherein

R^1 is hydrogen;

R^2 is hydrogen, C_{1-3} alkyl, C_{2-3} alkenyl, C_{2-6} alkynyl, C_{1-3} hydroxyalkyl, C_{2-3} alkoxyalkyl, halogen, -CN, -NO, $-NO_2$, $-C(O)R^{2a}$, $-N(R^{2a})C(O)R^{2b}$, $-N(R^{2a})(R^{2b})$, $-OR^{2a}$, or a 5 to 6 membered heteroaryl ring having 1 to 2 heteroatoms each independently N, O, or S;

R^{2a} and R^{2b} are each independently hydrogen or C_{1-3} alkyl;

R^3 is hydrogen, C_{1-3} alkyl, halogen, -CN or $-NO_2$; and

R^4 is hydrogen.

24. The compound of any one of claims 1 to 22, or a pharmaceutically acceptable salt thereof, wherein

R^1 is hydrogen;

R^2 is hydrogen, C_{1-3} alkyl, C_{2-3} alkenyl, C_{2-6} alkynyl, C_{1-3} hydroxyalkyl, C_{2-3} alkoxyalkyl, halogen, -CN, -NO, $-NO_2$, $-C(O)R^{2a}$, $-N(R^{2a})C(O)R^{2b}$, $-N(R^{2a})(R^{2b})$, $-OR^{2a}$, or a 5 to 6 membered heteroaryl ring having 1 to 2 heteroatoms each independently N, O, or S;

R^{2a} and R^{2b} are each independently hydrogen or C_{1-3} alkyl;

R^3 is hydrogen; and

R^4 is hydrogen.

25. The compound of any one of claims 1 to 24, or a pharmaceutically acceptable salt thereof, wherein

R^5 is C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} hydroxyalkyl, C_{2-6} alkoxyalkyl, C_{1-6} haloalkyl, C_{3-10} cycloalkyl, C_{1-6} alkyl-C_{3-10} cycloalkyl, C_{6-12} aryl, C_{1-6} alkyl-C_{6-12} aryl, C_{1-6} alkyl-(heterocycloalkyl), or C_{1-6} alkyl-(heteroaryl), wherein the alkyl is optionally substituted with R^{5a};

R^{5a} is $-OSi(R^{5a1})(R^{5a2})(R^{5a3})$;

~~R^{5a1}, R^{5a2}, and R^{5a3} are each independently C_{1-4} alkyl; and~~

~~the heterocycloalkyl is a 5 to 8 membered ring having 1 to 2 heteroatoms each independently N, O, or S; and~~

~~the heteroaryl is a 5 to 6 membered ring having 1 to 2 heteroatoms each independently N, O, or S.~~

~~26. The compound of any one of claims 1 to 25, or a pharmaceutically acceptable salt thereof, wherein~~

~~R^5 is C_{1-6} alkyl, C_{2-6} alkynyl, C_{2-6} alkoxyalkyl, C_{1-6} haloalkyl, C_{3-10} cycloalkyl, C_{1-6} alkyl-C_{3-10} cycloalkyl, C_{6-12} aryl, C_{1-6} alkyl-C_{6-12} aryl, or C_{1-6} alkyl-(heterocycloalkyl), wherein the alkyl is optionally substituted with R^{5a};~~

~~R^{5a} is $-OSi(R^{5a1})(R^{5a2})(R^{5a3})$;~~

~~R^{5a1}, R^{5a2}, and R^{5a3} are each independently C_{1-4} alkyl, wherein R^{5a1} and R^{5a2} are different; and~~

~~the heterocycloalkyl is a 5 to 6 membered ring having 1 to 2 heteroatoms each independently N or O.~~

~~27. The compound of any one of claims 1 to 25, or a pharmaceutically acceptable salt thereof, wherein~~

~~R^5 is C_{1-6} alkyl, C_{2-6} alkynyl, C_{2-3} alkoxyalkyl, C_{1-3} haloalkyl, C_{3-8} cycloalkyl, C_{1-3} alkyl-C_{3-8} cycloalkyl, phenyl, C_{1-3} alkyl-phenyl, or C_{1-3} alkyl-(heterocycloalkyl), wherein the alkyl is optionally substituted with R^{5a};~~

~~R^{5a} is $-OSi(R^{5a1})(R^{5a2})(R^{5a3})$;~~

~~R^{5a1}, R^{5a2}, and R^{5a3} are each independently Me or tBu, wherein R^{5a1} and R^{5a2} are different; and~~

~~the heterocycloalkyl is a 6 membered ring having 1 heteroatom N or O.~~

~~2866~~. The compound of any one of claims 1 to ~~26~~5, or a pharmaceutically acceptable salt thereof, wherein

R^5 is Me, Et, nPr, nBu, $-CH_2CMe_3$, $-CH_2C{\equiv}CMe$, $-CH_2CH_2C{\equiv}CH$, $-CH_2CH_2OMe$, $-CH_2CH_2OSi(Me)_2(tBu)$, CF_3, $-CH_2CF_2H$, $-CH_2CF_3$,



~~29. The compound of any one of claims 1 to 24, or a pharmaceutically acceptable salt thereof, wherein~~

~~R^5 is C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} hydroxyalkyl, C_{2-6} alkoxyalkyl, C_{1-6} haloalkyl, C_{1-6} alkyl-C_{3-10} cycloalkyl, C_{6-12} aryl, C_{1-6} alkyl-C_{6-12} aryl, C_{1-6} alkyl-(heterocycloalkyl), or C_{1-6} alkyl-(heteroaryl), wherein the alkyl is optionally substituted with R^{5a};~~

~~R^{5a} is $-OSi(R^{5a1})(R^{5a2})(R^{5a3})$;~~

~~R^{5a1}, R^{5a2}, and R^{5a3} are each independently C_{1-4} alkyl; and~~

~~the heterocycloalkyl is a 5 to 8 membered ring having 1 to 2 heteroatoms each independently N, O, or S; and~~

~~the heteroaryl is a 5 to 6 membered ring having 1 to 2 heteroatoms each independently N, O, or S.~~

~~30. The compound of any one of claims 1 to 24, or a pharmaceutically acceptable salt thereof, wherein~~

~~R^5 is C_{1-6} alkyl, C_{2-6} alkynyl, C_{2-6} alkoxyalkyl, C_{1-6} alkyl-C_{3-10} cycloalkyl, C_{6-12} aryl, C_{1-6} alkyl-C_{6-12} aryl, or C_{1-6} alkyl-(heterocycloalkyl), wherein the alkyl is optionally substituted with R^{5a};~~

~~R^{5a} is $-OSi(R^{5a1})(R^{5a2})(R^{5a3})$;~~

~~R^{5a1}, R^{5a2}, and R^{5a3} are each independently C_{1-4} alkyl, wherein R^{5a1} and R^{5a2} are different; and~~

~~the heterocycloalkyl is a 5 to 6 membered ring having 1 to 2 heteroatoms each independently N or O.~~

~~31. The compound of any one of claims 1 to 24, or a pharmaceutically acceptable salt thereof, wherein~~

~~R^5 is C_{1-6} alkyl, C_{2-6} alkynyl, C_{2-3} alkoxyalkyl, C_{1-3} alkyl-C_{3-8} cycloalkyl, phenyl, C_{1-3} alkyl-phenyl, or C_{1-3} alkyl-(heterocycloalkyl), wherein the alkyl is optionally substituted with R^{5a};~~

~~R^{5a} is $-OSi(R^{5a1})(R^{5a2})(R^{5a3})$;~~

~~R^{5a1}, R^{5a2}, and R^{5a3} are each independently Me or tBu, wherein R^{5a1} and R^{5a2} are different; and~~

~~the heterocycloalkyl is a 6 membered ring having 1 heteroatom N or O.~~

~~32. The compound of any one of claims 1 to 24, or a pharmaceutically acceptable salt thereof, wherein~~

~~R^5 is Me, Et, nPr, nBu, $-CH_2CMe_3$, $-CH_2C{\equiv}CMe$, $-CH_2CH_2C{\equiv}CH$, $-CH_2CH_2OMe$, $-CH_2CH_2OSi(Me)_2(tBu)$,~~



~~33. The compound of any one of claims 1 to 32, or a pharmaceutically acceptable salt thereof, wherein~~

~~R^6 is phenyl, naphthyl, thienyl, thiazolyl, pyridyl, pyrazinyl, pyrimidinyl, or dibenzofuryl, which are each optionally substituted with 1 or 2 R^{6a}.~~

~~34~~7. The compound of any one of claims 1 to ~~32~~6, or a pharmaceutically acceptable salt thereof, wherein

R^6 is phenyl or a 5 to 6 membered heteroaryl ring having 1 to 3 heteroatoms each independently N, O, or S, which are each optionally substituted with 1 or 2 R^{6a}.

~~35. The compound of any one of claims 1 to 34, or a pharmaceutically acceptable salt thereof, wherein~~

~~R^6 is phenyl, thienyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrrolyl, pyrazolyl, pyridyl, or pyrimidinyl, which are each optionally substituted with 1 or 2 R^{6a}.~~

~~36. The compound of any one of claims 1 to 33, or a pharmaceutically acceptable salt thereof, wherein R^6 is~~



~~37. The compound of any one of claims 1 to 33, or a pharmaceutically acceptable salt thereof, wherein R^6 is~~







~~38. The compound of any one of claims 1 to 36, or a pharmaceutically acceptable salt thereof, wherein R^7 is hydrogen, Me, Et, OMe, $-CH_2OH$, $-CH_2OMe$, $-CH_2NMe_2$, Cl, CHF_2, OH, NH_2, SMe, or~~



~~39~~8. The compound of any one of claims 1 to ~~36~~7, or a pharmaceutically acceptable salt thereof, wherein R^7 is hydrogen, Me, Et, OMe, $-CH_2NMe_2$, Cl, OH, NH_2, SMe, or



~~40~~9. The compound of claim 1 to ~~39~~8, or a pharmaceutically acceptable salt thereof, having the Formula (IIa):



(IIa),

wherein n is 0, 1, 2, or 3.

41. The compound of any one of claims 1 to 39, or a pharmaceutically acceptable salt thereof, having the Formula (I-1):



(I-1).

42. The compound of claim 1 to 39, or a pharmaceutically acceptable salt thereof, having the Formula (IIa-1):



(IIa-1).

43. The compound of any one of claims 1 to 42, or a pharmaceutically acceptable salt thereof, wherein

each R^{6a} is independently C_{1-6} alkyl, C_{2-6} alkynyl, C_{1-6} hydroxyalkyl, C_{1-6} alkoxy, C_{2-6} alkoxyalkyl, halogen, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, -CN, $-NO_2$, $-C(O)R^{6b}$, $-C(O)OR^{6b}$, $-C(O)N(R^{6b})(R^{6c})$, $-N(R^{6b})(R^{6c})$, $-OR^{6b}$, C_{3-10} cycloalkyl, C_{6-12} aryl, heterocycloalkyl, or heteroaryl, wherein the cycloalkyl, aryl, heterocycloalkyl, or heteroaryl is each optionally substituted with 1 to 3 R^{6e}, and the alkyl is optionally substituted with R^{6f};

each R^{6b} and R^{6c} is independently hydrogen or C_{1-6} alkyl;

each R^{6e} is independently C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} hydroxyalkyl, C_{1-6} alkoxy, C_{2-6} alkoxyalkyl, halogen, C_{1-6} haloalkyl, $-C(O)OR^{6e1}$, $-OC(O)R^{6e1}$, $-C(O)N(R^{6e1})(R^{6e2})$, $-N(R^{6e1})C(O)R^{6e2}$, $-OR^{6e1}$, $-S(O)_2N(R^{6e1})(R^{6e2})$, $-N(R^{6e1})S(O)_2(R^{6e2})$;

each R^{6e1} and R^{6e2} is independently hydrogen or C_{1-6} alkyl;

R^{6f} is $-OSi(R^{6f1})(R^{6f2})(R^{6f3})$; and

R^{6f1}, R^{6f2}, and R^{6f3} are each independently C_{1-6} alkyl.

44. The compound of any one of claims 1 to 43, or a pharmaceutically acceptable salt thereof, wherein

each R^{6a} is independently C_{1-3} alkyl, C_{2-3} alkynyl, C_{1-3} hydroxyalkyl, C_{1-3} alkoxy, C_{2-3} alkoxyalkyl, halogen, C_{1-3} haloalkyl, C_{1-3} haloalkoxy, $-CN$, $-NO_2$, $-C(O)R^{6b}$, $-C(O)OR^{6b}$, $-C(O)N(R^{6b})(R^{6c})$, $-N(R^{6b})(R^{6c})$, $-OR^{6b}$, C_{3-8} cycloalkyl, phenyl, a 5 to 6 membered heterocycloalkyl ring having 1 to 2 heteroatoms each independently N or O, or a 5 to 6 membered heteroaryl ring having 1 to 2 heteroatoms each independently N, O, or S, wherein the cycloalkyl, phenyl, heterocycloalkyl, or heteroaryl is each optionally substituted with 1 to 2 R^{6e}, and the alkyl is optionally substituted with R^{6f};

each R^{6b} and R^{6c} is independently hydrogen or C_{1-3} alkyl;

each R^{6e} is independently C_{1-6} alkyl, C_{1-6} hydroxyalkyl, C_{1-6} alkoxy, C_{2-6} alkoxyalkyl, halogen, C_{1-6} haloalkyl, $-C(O)OR^{6e1}$, $-OC(O)R^{6e1}$, $-N(R^{6e1})C(O)R^{6e2}$, $-OR^{6e1}$;

each R^{6e1} and R^{6e2} is independently hydrogen or C_{1-6} alkyl;

R^{6f} is $-OSi(R^{6f1})(R^{6f2})(R^{6f3})$;

R^{6f1}, R^{6f2}, and R^{6f3} are each independently Me or tBu.

45. The compound of any one of claims 1 to 44, or a pharmaceutically acceptable salt thereof, wherein

each R^{6e} is independently C_{1-6} alkyl, C_{1-3} alkoxy, halogen, C_{1-6} haloalkyl, $-N(R^{6e1})C(O)R^{6e2}$, or $-OR^{6e1}$; and

each R^{6e1} and R^{6e2} is independently hydrogen or C_{1-3} alkyl.

46. The compound of any one of claims 1 to 42, or a pharmaceutically acceptable salt thereof, wherein each R^{6n} is independently Me or CO_2tBu.

47. The compound of any one of claims 1 to 42, or a pharmaceutically acceptable salt thereof, wherein each R^{6h} is independently Me, $-CH_2OH$, $-CH_2NHMe$, OMe, NH_2, CF_3, CN, $-(CO)Me$, $-(CO)$tBu, $-(CO)-CH_2OH$, CO_2Me, CO_2tBu, =O, or



48. The compound of any one of claims 1 to 42, or a pharmaceutically acceptable salt thereof, wherein each R^{6m} is independently OH, CF_3, CN, CO_2H, $CONH_2$, NMe_2, SO_2Me, or



49. The compound of any one of claims 1 to 42, or a pharmaceutically acceptable salt thereof, wherein

each R^{6e} is independently Me, Et, iPr, tBu, $-CH_2OH$, $-C(OH)Me_2$, -OMe, -OEt, $-OCH_2CH_2CH_3$, $-CH_2OMe$, $-OCH_2CH_2NMe_2$, F, Cl, Br, CHF_2, $-CF_3$, $-CH_2CHF_2$, $-CH_2CF_3$, $-CF_2CH_3$, $-C(CH_3)_2CF_3$, OCF_3, $-OCH_2CF_3$, $-OCH(CH_3)CF_3$, CN, -C(O)Me, -C(O)tBu, CO_2H, CO_2Me, CO_2tBu, $C(O)NH_2$, =O, OH, NH_2, NMe_2, $-NMeCH_2CH_2OMe$, -NHC(O)Me, -NHC(O)tBu, $-NHCO_2tBu$, SO_2Me, SO_2Et, $SO_2(iPr)$, $SO_2(iBu)$, SO_2CF_3, $-CH_2SO_2Me$, $SO(N{=}H)Me$, SO_2NH_2, SO_2NHMe, SO_2NMe_2, $-SO_2NHCH_2CH_2OH$, $-NHSO_2Me$, SF_5, $-POMe_2$,











~~50. The compound of any one of claims 1 to 42, or a pharmaceutically acceptable salt thereof, wherein~~

~~each R^{6e} is independently Me, Et, iPr, tBu, $-CH_2OH$, $-C(OH)Me_2$, -OMe, -OEt, $-OCH_2CH_2CH_3$, $-CH_2OMe$, $-OCH_2CH_2NMe_2$, F, Cl, Br, CHF_2, $-CF_3$, $-CH_2CHF_2$, $-CH_2CF_3$, $-CF_2CH_3$, $-C(CH_3)_2CF_3$, OCF_3, $-OCH_2CF_3$, $-OCH(CH_3)CF_3$, CN, -C(O)Me, -C(O)tBu, CO_2H, CO_2Me, CO_2tBu, $C(O)NH_2$, =O, OH, NH_2, NMe_2, $-NMeCH_2CH_2OMe$, -NHC(O)Me, -NHC(O)tBu, $-NHCO_2tBu$, SO_2Me, SO_2Et, $SO_2(iPr)$, $SO_2(iBu)$, SO_2CF_3, $-CH_2SO_2Me$, $SO(N{=}H)Me$, SO_2NH_2, SO_2NHMe, SO_2NMe_2, $-SO_2NHCH_2CH_2OH$, $-NHSO_2Me$, SF_5, $-POMe_2$,~~





51. The compound of any one of claims 1 to 45, or a pharmaceutically acceptable salt thereof, wherein

each R^{6e} is independently Me, Et, tBu, -OMe, F, Cl, $-CF_3$, -NHC(O)Me, or -OH.

52. The compound of any one of claims 1 to 42, or a pharmaceutically acceptable salt thereof, wherein each R^{6j} is independently OH, OMe, CH_2OMe, F, CHF_2, CF_3, CN, NH_2, $NH(CO)CF_3$, NH(CO)OtBu, SO_2Me, $Si(iPr)_3$,



53. The compound of any one of claims 1 to 42, or a pharmaceutically acceptable salt thereof, wherein each R^{6j} is independently OH, OMe, F, CHF_2, CF_3, NH_2, NH(CO)OtBu, SO_2Me, $Si(iPr)_3$,



~~54. The compound of any one of claims 1 to 42, or a pharmaceutically acceptable salt thereof, wherein each R^{6p} is independently Me, Et, iPr, F, Cl, CH_2F, CHF_2, CF_3, CF_2CH_3, CH_2CF_3, =O, or OH.~~

~~55. The compound of any one of claims 1 to 42, or a pharmaceutically acceptable salt thereof, wherein each R^{6p} is independently Me, Cl, CF_3, =O, or OH.~~

~~56~~10. The compound of any one of claims 1 to ~~42~~9, or a pharmaceutically acceptable salt thereof, wherein

each R^{6a} is independently













~~57. The compound of any one of claims 1 to 44, or a pharmaceutically acceptable salt thereof, wherein~~

~~each R^{6a} is independently Me, Et, -C≡CMe, -OMe, -CH_2OH, -CH_2OMe, -$CH_2OSi(Me)_2(tBu)$, F, Cl, Br, I, -CH_2F, -CF_3, -OCF_3, -CN, -NO_2, -C(O)H, -COOH, -COOMe, -$CONH_2$, -NH_2, -OH, cyclopropyl, cyclohexyl, phenyl,~~



~~58. The compound of any one of claims 1 to 57, or a pharmaceutically acceptable salt thereof, wherein~~

~~R^5 is C_{1-6} alkyl, C_{2-6} alkynyl, C_{2-3} alkoxyalkyl, C_{1-3} alkyl-C_{3-8} cycloalkyl, phenyl, C_{1-3} alkyl-phenyl, or C_{1-3} alkyl-(heterocycloalkyl);~~

~~R^6 is phenyl, optionally substituted with R^{6a};~~

~~R^{6a} is independently C_{1-3} alkyl, C_{2-3} alkynyl, C_{1-3} hydroxyalkyl, C_{1-3} alkoxy, C_{2-3} alkoxyalkyl, halogen, C_{1-3} haloalkyl, C_{1-3} haloalkoxy, -CN, $-NO_2$, $-C(O)R^{6b}$, $-C(O)OR^{6b}$, $-C(O)N(R^{6b})(R^{6e})$, $-N(R^{6b})(R^{6e})$, -OH, or phenyl, wherein the phenyl is optionally substituted with R^{6e};~~

~~R^{6b} and R^{6c} are each independently hydrogen or C_{1-3} alkyl;~~

~~R^{6e} is C_{1-6} alkyl, halogen, C_{1-3} haloalkyl, $-N(R^{6e1})C(O)R^{6e2}$, or $-OR^{6e1}$;~~

~~R^{6e1} and R^{6e2} is independently hydrogen or C_{1-3} alkyl; and~~

~~the heterocycloalkyl is a 6 membered ring having 1 heteroatom N or O.~~

~~59. The compound of any one of claims 1 to 58, or a pharmaceutically acceptable salt thereof, having the Formula (Ib):~~



~~(Ib),~~

~~wherein m is 0, 1, 2, or 3.~~

~~60. The compound of any one of claims 1 to 58, or a pharmaceutically acceptable salt thereof, wherein R^6 is~~




























































, or .

~~61. The compound of any one of claims 1 to 41, or a pharmaceutically acceptable salt thereof, wherein R^6 is~~















~~62. The compound of any one of claims 1 to 24, or a pharmaceutically acceptable salt thereof, having the Formula (Ic):~~



~~(Ic),~~

~~wherein~~

~~Ring A is a 5 to 8 membered heterocycloalkyl optionally having 1 to 2 additional heteroatoms each independently N, O, or S, and optionally wherein Ring A is substituted with 1 or 2 R^{6g}; and~~

~~n is 0, 1, or 2.~~

~~63. The compound of any one of claims 1 to 24, or a pharmaceutically acceptable salt thereof, wherein each R^{6g} is methyl.~~

~~64~~11. The compound of any one of claims 1 ~~to 24, 33 to 35, and 38 10,~~ or a pharmaceutically acceptable salt thereof, having the structure of Formula (IIc):



(IIc),

wherein

Ring A is a 5 to 8 membered heterocycloalkyl optionally having 1 to 2 additional heteroatoms each independently N, O, or S, and optionally wherein Ring A is substituted with 1 or 2 R^{6g}; and

n is 0, 1, or 2,

optionally  has the structure





optionally  has the structure











65. ~~The compound of claim 64, wherein~~

~~R^1 is hydrogen, C_{1-3} alkyl, or halogen;~~

~~R^2 is hydrogen, C_{1-3} alkyl, C_{1-3} hydroxyalkyl, C_{2-3} alkoxyalkyl, halogen, or -CN;~~

~~R^3 is hydrogen, C_{1-3} alkyl, or halogen;~~

~~R^4 is hydrogen, C_{1-3} alkyl, or halogen;~~

~~each R^{6a} is independently C_{1-3} alkyl, C_{2-3} alkenyl, or C_{2-3} alkynyl, wherein the alkynyl is optionally substituted with 1 to 3 R^{6j};~~

~~each R^{6j} is independently C_{2-3} alkoxyalkyl, halogen, C_{1-3} haloalkyl, C_{1-3} haloalkoxy, -CN, C_{3-8} cycloalkyl, or heterocycloalkyl, wherein the cycloalkyl or heterocycloalkyl is optionally substituted with 1 to 3 R^{6p};~~

~~each R^{6p} is independently C_{1-3} alkyl, C_{1-3} hydroxyalkyl, C_{2-3} alkoxyalkyl, halogen, C_{1-3} haloalkyl, C_{1-3} haloalkoxy, or -CN; and~~

~~R^7 is hydrogen, C_{1-3} alkyl, C_{2-3} alkoxyalkyl, C_{1-3} haloalkyl, or $-NH_2$.~~

~~66~~12. The compound of claim ~~64 or 65~~11, wherein
R^1 is hydrogen or halogen, optionally R^1 is hydrogen or F.

~~67. The compound of any one of claims 64 to 66, wherein R^1 is hydrogen or F.~~

~~68~~13. The compound of any one of claims ~~64~~ 11 and 12~~to 66~~, wherein
R^4 is hydrogen, C_{1-3} alkyl, or halogen, optionally R^4 is hydrogen, Me, or F.

~~69. The compound of any one of claims 64 to 68, wherein R^4 is hydrogen, Me, or F.~~

~~70. The compound of any one of claims 1 to 24, 33 to 35, and 38, or a pharmaceutically acceptable salt thereof, having the structure of Formula (IIc-1):~~



~~(IIc-1),~~

~~wherein~~

~~Ring A is a 5 to 8 membered heterocycloalkyl optionally having 1 to 2 additional heteroatoms each independently N, O, or S, and optionally wherein Ring A is substituted with 1 or 2 R^{6g}; and~~

~~n is 0, 1, or 2.~~

~~71. The compound of any one of claims 62 and 64 to 70, or a pharmaceutically acceptable salt thereof, wherein~~


~~has the structure~~


~~,~~

~~,~~

~~,~~

~~,~~


~~, or~~

~~.~~

~~72. The compound of any one of claims 1 to 24, 33 to 35, and 38, or a pharmaceutically acceptable salt thereof, having the structure of Formula (IIc-2):~~


~~(IIc-2),~~

~~wherein n is 0, 1, or 2.~~

~~73. The compound of any one of claims 1 to 24, and 62 to 70, or a pharmaceutically acceptable salt thereof, wherein~~


has the structure





74. The compound of any one of claims 1 to 24, or a pharmaceutically acceptable salt thereof, wherein



has the structure



75. The compound of claim 64 or 70, or a pharmaceutically acceptable salt thereof, wherein

R^2 is hydrogen, C_{1-3} alkyl, C_{1-3} hydroxyalkyl, C_{2-3} alkoxyalkyl, halogen, or -CN;

R^3 is hydrogen, C_{1-3} alkyl, or halogen;

each R^{6a} is independently C_{1-3} alkyl, C_{2-3} alkenyl, or C_{2-3} alkynyl, wherein the alkynyl is optionally substituted with 1 to 3 R^{6j};

each R^{6j} is independently C_{2-3} alkoxyalkyl, halogen, C_{1-3} haloalkyl, C_{1-3} haloalkoxy, -CN, C_{3-8} cycloalkyl, or heterocycloalkyl, wherein the cycloalkyl or heterocycloalkyl is optionally substituted with 1 to 3 R^{6p};

each R^{6p} is independently C_{1-3} alkyl, C_{1-3} hydroxyalkyl, C_{2-3} alkoxyalkyl, halogen, C_{1-3} haloalkyl, C_{1-3} haloalkoxy, or -CN;

R^7 is hydrogen or C_{1-3} alkyl; and



has the structure 

.

~~76~~14. The compound of any one of claims ~~75~~11-13, or a pharmaceutically acceptable salt thereof, wherein R^2 is hydrogen, halogen, or -CN, optionally R^2 is hydrogen, F, or Cl.

~~77. The compound of claim 75 or 76, or a pharmaceutically acceptable salt thereof, wherein R^2 is hydrogen, F, or Cl.~~

~~78~~15. The compound of any one of claims ~~75~~ 11 to ~~77~~14, or a pharmaceutically acceptable salt thereof, wherein R^3 is hydrogen, F, or Cl.

~~79. The compound of any one of claims 75 to 78, or a pharmaceutically acceptable salt thereof, wherein each R^{6a} is independently C_{2-3} alkynyl or halogen, wherein the alkynyl is optionally substituted with 1 to 3 R^{6j}.~~

~~80. The compound of any one of claims 75 to 79, or a pharmaceutically acceptable salt thereof, wherein each R^{6a} is~~

~~  ~~

~~substituted with 1 R^{6j}.~~

~~81. The compound of any one of claims 75 to 80, or a pharmaceutically acceptable salt thereof, wherein each R^{6j} is independently C_{2-3} alkoxyalkyl, halogen, C_{1-3} haloalkyl, -CN, C_{3-6} cycloalkyl, or heterocycloalkyl, wherein the cycloalkyl or heterocycloalkyl is optionally substituted with 1 to 3 R^{6p}, and each heterocycloalkyl is a 3 to 6 membered ring having 1 to 2 heteroatoms each independently N, O or S.~~

82. The compound of any one of claims 75 to 81, or a pharmaceutically acceptable salt thereof, wherein each R^{6j} is independently halogen, C_{1-3} haloalkyl, C_{3-6} cycloalkyl, or heterocycloalkyl, wherein the cycloalkyl or heterocycloalkyl is optionally substituted with 1 to 2 R^{6p}, and each heterocycloalkyl is a 3 to 6 membered ring having 1 to 2 heteroatoms each independently N, O or S.

83. The compound of any one of claims 75 to 82, or a pharmaceutically acceptable salt thereof, wherein each R^{6j} is independently halogen, C_{1-3} haloalkyl, or C_{3-6} cycloalkyl, wherein the cycloalkyl is optionally substituted with one R^{6p}.

84. The compound of any one of claims 75 to 83, or a pharmaceutically acceptable salt thereof, wherein each R^{6j} is independently F, CH_2F, CHF_2, CF_3, CH_2CF_3, CF_2CH_3, or cyclopropyl, wherein the cyclopropyl is optionally substituted with one R^{6p}.

85. The compound of any one of claims 75 to 84, or a pharmaceutically acceptable salt thereof, wherein each R^{6p} is independently C_{1-3} alkyl, C_{1-3} hydroxyalkyl, halogen, C_{1-3} haloalkyl, or CN.

86. The compound of any one of claims 75 to 85, or a pharmaceutically acceptable salt thereof, wherein each R^{6p} is independently Me, Et, CH_2OH, F, CH_2F, CHF_2, CF_3, CH_2CF_3, CF_2CH_3, or CN.

87. The compound of any one of claims 75 to 86, or a pharmaceutically acceptable salt thereof, wherein



has the structure



881616. The A compound of any one of claims 1 to 74, or a pharmaceutically acceptable salt thereof, having the structure of a compound in Table 1A, Table 1B, Table 1C, Table 1D, Table 1E, Table 1F, Table 1G, Table 1H, Table 1I, Table 1J, Table 2A, Table 2B, Table 2C, Table 2D, Table 2E, Table 2F, Table 2G, Table 2H, Table 2I, Table 2J, Table 2K, Table 2L, Table 3A, Table 3B, Table 3C, Table 3D, Table 3E, Table 3F, Table 3G, Table 3H, Table 3I, Table 3J, or Table 3K, or a pharmaceutically acceptable salt thereof.

89. The compound of any one of claims 1 to 88, or a pharmaceutically acceptable salt thereof, having the structure:



~~90. The compound of any one of claims 1 to 88 having the structure:~~



~~91. The compound of any one of claims 1 to 88, or a pharmaceutically acceptable salt thereof, having the structure:~~



~~92. The compound of any one of claims 1 to 88 having the structure:~~



~~93. The compound of any one of claims 1 to 88, or a pharmaceutically acceptable salt thereof, having the structure:~~



~~94. The compound of any one of claims 1 to 88 having the structure:~~



~~95. The compound of any one of claims 1 to 88, or a pharmaceutically acceptable salt thereof, having the structure:~~



~~96. The compound of any one of claims 1 to 88 having the structure:~~



~~97. The compound of any one of claims 1 to 88, or a pharmaceutically acceptable salt thereof, having the structure:~~



~~98. The compound of any one of claims 1 to 88 having the structure:~~



~~99. The compound of any one of claims 1 to 88, or a pharmaceutically acceptable salt thereof, having the structure:~~



~~100. The compound of any one of claims 1 to 88 having the structure:~~



17. A compound selected from the group consisting of

















,


, and

, or a pharmaceutically acceptable salt thereof.

18. The compound of claim 17 having the structure:


,

,


,

,

,

,






pharmaceutically acceptable salt thereof.

~~101~~19. A pharmaceutical composition comprising a pharmaceutically effective amount of a compound of any one of claims 1-~~18~~10~~0018~~, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

~~102. The pharmaceutical composition of claim 101, further comprising one or more additional therapeutic agents.~~

~~103. The pharmaceutical composition of claim 102, wherein the one or more additional therapeutic agents is independently an anti-neoplastic agent, nivolumab, pembrolizumab, atezolizumab, ipilimumab, chemotherapy, radiation therapy, or resection therapy.~~

~~104. The pharmaceutical composition of claim 102, wherein the one or more additional therapeutic agents is independently rituxan, doxorubicin, gemcitabine, nivolumab, pembrolizumab, artezolizumab, nivolumab, pembrolizumab, atezolizumab, or ipilimumab.~~

~~105. The pharmaceutical composition of claim 102, wherein the one or more additional therapeutic agents is a PD-1/PD-L1 inhibitor.~~

~~106. The pharmaceutical composition of claim 102, wherein the one or more additional therapeutic agents is a vaccine.~~

~~107. A pharmaceutical composition for use in treating a cancer, comprising a pharmaceutically effective amount of a compound of any one of claims 1-100, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.~~

~~108. A pharmaceutical composition for use in treating an HIV or hepatitis B virus infection, comprising a pharmaceutically effective amount of a compound of any one of claims 1-100, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.~~

~~109. A method of inhibiting DGKα in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of any one of claims 1-100, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of any one of claims 101 to 106.~~

~~110~~20. Use of a~~A~~ compound of any one of claims 1-18, or a pharmaceutically acceptable salt thereof, ~~or a pharmaceutical composition of claim 19,~~ in the manufacture of a medicament ~~A method of~~for ~~use in~~ the treatment of a ~~treating~~ cancer in a subject in need thereof, ~~the method comprising administering to the subject a therapeutically effective amount of a compound of any one of claims 1-100, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of any one of claims 101 to 106~~optionally the cancer is pancreatic cancer, bladder cancer, colorectal cancer, breast cancer, prostate cancer, renal cancer, hepatocellular cancer, lung cancer, ovarian cancer, cervical cancer, gastric cancer, esophageal cancer, head and neck cancer, melanoma, neuroendocrine cancer, CNS cancer, brain cancer, bone cancer, soft tissue sarcoma, non-small cell lung cancer, small-cell lung cancer or colon cancer, optionally the cancer is acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), myelodysplastic syndrome (MDS), myeloproliferative disease (MPD), chronic myeloid leukemia (CML), multiple myeloma (MM), non-Hodgkin's lymphoma (NHL), mantle cell lymphoma (MCL), follicular lymphoma, Waldestrom's macroglobulinemia (WM), T-cell lymphoma, B-cell lymphoma or diffuse large B-cell lymphoma (DLBCL).

~~111. The method of claim 110, wherein the cancer is pancreatic cancer, bladder cancer, colorectal cancer, breast cancer, prostate cancer, renal cancer, hepatocellular cancer, lung~~

~~cancer, ovarian cancer, cervical cancer, gastric cancer, esophageal cancer, head and neck cancer, melanoma, neuroendocrine cancer, CNS cancer, brain cancer, bone cancer, soft tissue sarcoma, non-small cell lung cancer, small-cell lung cancer or colon cancer.~~

~~112. The method of claim 110, wherein the cancer is acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), myelodysplastic syndrome (MDS), myeloproliferative disease (MPD), chronic myeloid leukemia (CML), multiple myeloma (MM), non-Hodgkin's lymphoma (NHL), mantle cell lymphoma (MCL), follicular lymphoma, Waldestrom's macroglobulinemia (WM), T-cell lymphoma, B-cell lymphoma or diffuse large B-cell lymphoma (DLBCL).~~

~~113. The method of any one of claims 110 to 112, further comprising administering one or more additional therapeutic agents to the subject.~~

~~114. The method of claim 113, wherein the one or more additional therapeutic agents is independently an anti-neoplastic agent, nivolumab, pembrolizumab, atezolizumab, ipilimumab, chemotherapy, radiation therapy, or resection therapy.~~

~~115. The method of claim 113, wherein the one or more additional therapeutic agents is independently rituxan, doxorubicin, gemcitabine, nivolumab, pembrolizumab, artezolizumab, nivolumab, pembrolizumab, atezolizumab, or ipilimumab.~~

~~116. The method of claim 113, wherein the one or more additional therapeutic agents is a PD-1/PD-L1 inhibitor.~~

~~117. The method of claim 113, wherein the one or more additional therapeutic agents comprises one or more populations of immune cells selected from the group consisting of: natural killer (NK) cells, NK-T cells, T cells, cytokine-induced killer (CIK) cells, macrophage (MAC) cells, tumor infiltrating lymphocytes (TILs) and dendritic cell (DCs).~~

~~118. The method of claim 113, wherein the one or more additional therapeutic agents comprises a population of T cells selected from the group consisting of: alpha/beta TCR T cells, gamma/delta TCR T cells, regulatory T (Treg) cells and TRuC™ T cells.~~

~~119. The method of claim 113, wherein the one or more additional therapeutic agents comprises a population of NK-92 cells.~~

~~120. The method of any one of claims 117 to 119, wherein the one or more populations of immune cells comprise one or more chimeric antigen receptors (CARs).~~

~~121. The method of any one of claims 117 to 120, wherein the cells are allogeneic to an intended recipient.~~

~~122. The method of claim 113, wherein the one or more additional therapeutic agents comprises an immunotherapy, an immunostimulatory therapy, a cytokine therapy, a chemokine therapy, a cellular therapy, a gene therapy, or combinations thereof.~~

~~123. The method of claim 122, wherein the immunotherapy comprises co-administering one or more antibodies or antigen-binding antibody fragments thereof, or antibody-drug conjugates thereof, CD3-targeting multi-specific molecules, CD16-targeting multi-specific molecules, or non-immunoglobulin antigen-binding domains or antibody mimetic proteins directed against one or more targets or tumor associated antigens (TAAs).~~

~~124. The method of claim 113, wherein the one or more additional therapeutic agents comprises a vaccine.~~

~~125. A method of treating an HIV or hepatitis B virus infection in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of any one of claims 1-100, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of any one of claims 101 to 105.~~

~~126. The method of claim 125, further comprising one or more additional therapeutic agents.~~

~~127. The method of claim 126, wherein the one or more additional therapeutic agents comprises a vaccine.~~

~~128. A method for manufacturing a medicament for treating cancer in a subject in need thereof, characterized in that a compound of any one of claims 1-100, or a pharmaceutically acceptable salt thereof, is used.~~

~~129. A method for manufacturing a medicament for inhibiting cancer metastasis in a subject in need thereof, characterized in that a compound of any one of claims 1-100, or a pharmaceutically acceptable salt thereof, is used.~~

~~130. A method for manufacturing a medicament for treating an HIV or hepatitis B virus infection in a subject in need thereof, characterized in that a compound of any one of claims 1-100, or a pharmaceutically acceptable salt thereof, is used.~~

~~131. Use of the compound of any one of claims 1-100, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of cancer in a subject.~~

~~132. Use of the compound of any one of claims 1-100, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for inhibiting cancer metastasis in a subject.~~

~~133. Use of the compound of any one of claims 1-100, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of an HIV or hepatitis B virus infection in a subject.~~

~~134. The compound of any one of claims 1-100, or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer in a subject in need thereof.~~

~~135. The compound of any one of claims 1-100, or a pharmaceutically acceptable salt thereof, for use in inhibiting cancer metastasis in a subject in need thereof.~~

~~136. The compound of any one of claims 1-100, or a pharmaceutically acceptable salt thereof, for use in the treatment of an HIV or hepatitis B virus infection in a subject in need thereof.~~

137. The compound of any one of claims 1-100, or a pharmaceutically acceptable salt thereof, for use in therapy.

138. A method of inhibiting DGKα in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound of Formula (I):



(I)

or a pharmaceutically acceptable salt thereof, wherein

R^1 is hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, halogen, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, or -CN;

R^2 is hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} hydroxyalkyl, C_{1-6} aminoalkyl, C_{1-6} alkoxy, C_{2-6} alkoxyalkyl, halogen, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, -CN, -NO, $-NO_2$, $-C(O)R^{2a}$, $-C(O)OR^{2a}$, $-OC(O)R^{2a}$, $-C(O)N(R^{2a})(R^{2b})$, $-N(R^{2a})C(O)R^{2b}$, $-OC(O)N(R^{2a})(R^{2b})$, $-N(R^{2a})C(O)OR^{2b}$, $-C(=NR^{2a})N(R^{2b})(R^{2c})$, $-N(R^{2a})(R^{2b})$, $-N(R^{2a})N(R^{2b})(R^{2c})$, $-N(R^{2a})N=C(R^{2b})(OR^{2c})$, $-OR^{2a}$, $-SR^{2a}$, $-S(O)R^{2a}$, $-S(O)(NR^{2a})(R^{2b})$, $-S(NR^{2a})(NR^{2b})(R^{2c})$, $-S(O)_2R^{2a}$, $-S(O)_2N(R^{2a})(R^{2b})$, $-N(R^{2a})S(O)_2(R^{2b})$, $-P(R^{2a})(R^{2b})$, $-P(O)(R^{2a})(R^{2b})$, $-P(O)(OR^{2a})(R^{2b})$, $-P(O)(OR^{2a})(OR^{2b})$, C_{3-10} cycloalkyl, C_{1-6} alkyl-C_{3-10} cycloalkyl, C_{6-12} aryl, C_{1-6} alkyl-C_{6-12} aryl, heterocycloalkyl, C_{1-6} alkyl-(heterocycloalkyl), heteroaryl, or C_{1-6} alkyl-(heteroaryl), wherein each alkyl, alkenyl or alkynyl is independently optionally substituted with 1 to 3 R^{2d} groups, each cycloalkyl is optionally substituted with 1 to 3 R^{2e} groups, each aryl is optionally substituted with 1 to 3 R^{2f} groups, each heterocycloalkyl is optionally substituted with 1 to 3 R^{2g} groups, and each heteroaryl is optionally substituted with 1 to 3 R^{2h} groups;

each R^{2a}, R^{2b}, and R^{2c} is independently hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} hydroxyalkyl, C_{1-6} aminoalkyl, C_{2-6} alkoxyalkyl, C_{1-6} haloalkyl, C_{3-10} cycloalkyl, C_{1-6} alkyl-C_{3-10} cycloalkyl, C_{6-12} aryl, C_{1-6} alkyl-C_{6-12} aryl,

heterocycloalkyl, C_{1-6} alkyl-(heterocycloalkyl), heteroaryl, or C_{1-6} alkyl-(heteroaryl), wherein the aryl or heteroaryl is optionally substituted with 1 to 3 R^{2j};

alternatively, R^{2a}, R^{2b}, and R^{2c} when attached to the same atom can be combined with the atom to which they are attached to form a heterocycloalkyl;

each R^{2d} is independently -CN, $-C(O)R^{2d1}$, $-C(O)OR^{2d1}$, $-OC(O)R^{2d1}$, $-C(O)N(R^{2d1})(R^{2d2})$, $-N(R^{2d1})C(O)R^{2d2}$, $-OC(O)N(R^{2d1})(R^{2d2})$, $-N(R^{2d1})C(O)OR^{2d2}$, $-N(R^{2d1})(R^{2d2})$, =O, $-OR^{2d1}$, $-SR^{2d1}$, $-S(O)R^{2d1}$, $-S(O)(NR^{2d1})(R^{2d2})$, $-S(O)_2R^{2d1}$, $-S(O)N(R^{2d1})(R^{2d2})$, $-N(R^{2d1})S(O)_2R^{2d2}$, C_{3-10} cycloalkyl, C_{1-6} alkyl-C_{3-10} cycloalkyl, C_{6-12} aryl, C_{1-6} alkyl-C_{6-12} aryl, heterocycloalkyl, C_{1-6} alkyl-(heterocycloalkyl), heteroaryl, or C_{1-6} alkyl-(heteroaryl);

each R^{2d1} and R^{2d2} is independently hydrogen, C_{1-6} alkyl, C_{1-6} hydroxyalkyl, C_{1-6} aminoalkyl, C_{2-6} alkoxyalkyl, or C_{1-6} haloalkyl;

each R^{2e}, R^{2f}, R^{2g}, and R^{2h} is independently hydrogen, C_{1-6} alkyl, C_{1-6} hydroxyalkyl, C_{1-6} aminoalkyl, C_{1-6} alkoxy, C_{2-6} alkoxyalkyl, halogen, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, -CN, or -OH;

each R^{2j} is independently C_{1-6} alkyl, C_{1-6} hydroxyalkyl, C_{1-6} aminoalkyl, C_{1-6} alkoxy, C_{2-6} alkoxyalkyl, halogen, C_{1-6} haloalkyl, or C_{1-6} haloalkoxy;

R^3 is hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} hydroxyalkyl, C_{1-6} aminoalkyl, C_{1-6} alkoxy, C_{2-6} alkoxyalkyl, halogen, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, -CN, -NO, $-NO_2$, $-C(O)R^{3a}$, $-C(O)OR^{3a}$, $-OC(O)R^{3a}$, $-C(O)N(R^{3a})(R^{3b})$, $-N(R^{3a})C(O)R^{3b}$, $-OC(O)N(R^{3a})(R^{3b})$, $-N(R^{3a})C(O)OR^{3b}$, $-C(=NR^{3a})N(R^{3b})(R^{3c})$, $-N(R^{3a})(R^{3b})$, $-N(R^{3a})N(R^{3b})(R^{3c})$, $-N(R^{3a})N=C(R^{3b})(OR^{3c})$, $-OR^{3a}$, $-SR^{3a}$, $-S(O)R^{3a}$, $-S(O)(NR^{3a})(R^{3b})$, $-S(NR^{3a})(NR^{3b})(R^{3c})$, $-S(O)_2R^{3a}$, $-S(O)_2N(R^{3a})(R^{3b})$, $-N(R^{3a})S(O)_2(R^{3b})$, $-P(R^{3a})(R^{3b})$, $-P(O)(R^{3a})(R^{3b})$, $-P(O)(OR^{3a})(R^{3b})$, $-P(O)(OR^{3a})(OR^{3b})$, C_{3-10} cycloalkyl, C_{1-6} alkyl-C_{3-10} cycloalkyl, C_{6-12} aryl, C_{1-6} alkyl-C_{6-12} aryl, heterocycloalkyl, C_{1-6} alkyl-(heterocycloalkyl), heteroaryl, or C_{1-6} alkyl-(heteroaryl), wherein each alkenyl or alkynyl is independently optionally substituted with 1 to 3 R^{3d} groups, each cycloalkyl is optionally substituted with 1 to 3 R^{3e} groups, each aryl is optionally substituted with 1 to 3 R^{3f} groups, each

heterocycloalkyl is optionally substituted with 1 to 3 R^{3g} groups, and each heteroaryl is optionally substituted with 1 to 3 R^{3h} groups;

each R^{3a}, R^{3b}, and R^{3c} is independently hydrogen, C_{1-6} alkyl, C_{1-6} hydroxyalkyl, C_{2-6} alkoxyalkyl, C_{1-6} haloalkyl, C_{3-10} cycloalkyl, C_{1-6} alkyl-C_{3-10} cycloalkyl, C_{6-12} aryl, C_{1-6} alkyl-C_{6-12} aryl, heterocycloalkyl, or heteroaryl;

alternatively, R^{3a}, R^{3b}, and R^{3c} when attached to the same atom can be combined with the atom to which they are attached to form a heterocycloalkyl;

each R^{3d} is independently $-N(R^{3d1})(R^{3d2})$, $-OR^{3d1}$, C_{3-10} cycloalkyl, C_{1-6} alkyl-C_{3-10} cycloalkyl, C_{6-12} aryl, C_{1-6} alkyl-C_{6-12} aryl, heterocycloalkyl, or heteroaryl;

each R^{3d1} and R^{3d2} is independently hydrogen, C_{1-6} alkyl, or $-C(O)O-(C_{1-6}$ alkyl);

each R^{3e}, R^{3f}, R^{3g}, and R^{3h} is independently hydrogen, C_{1-6} alkyl, C_{1-6} alkoxy, halogen, C_{1-6} haloalkyl or C_{1-6} haloalkoxy;

R^4 is hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, halogen, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, or $-CN$;

R^5 is hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} hydroxyalkyl, C_{2-6} alkoxyalkyl, C_{1-6} haloalkyl, C_{3-10} cycloalkyl, C_{1-6} alkyl-C_{3-10} cycloalkyl, C_{6-12} aryl, C_{1-6} alkyl-C_{6-12} aryl, heterocycloalkyl, C_{1-6} alkyl-(heterocycloalkyl), heteroaryl, or C_{1-6} alkyl-(heteroaryl), wherein the alkyl is optionally substituted with R^{5a};

R^{5a} is $-OSi(R^{5a1})(R^{5a2})(R^{5a3})$;

R^{5a1}, R^{5a2}, and R^{5a3} are each independently C_{1-6} alkyl; and

R^6 is C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, C_{6-12} aryl, or heteroaryl, wherein the aryl or heteroaryl are each optionally substituted with 1 to 3 R^{6a};

each R^{6a} is independently C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} hydroxyalkyl, C_{1-6} aminoalkyl, C_{1-6} alkoxy, C_{2-6} alkoxyalkyl, halogen, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, $-CN$, $-NO_2$, $-C(O)R^{6b}$, $-C(O)OR^{6b}$, $-OC(O)R^{6b}$, $-C(O)N(R^{6b})(R^{6e})$, $-N(R^{6b})C(O)R^{6e}$, $-C(=NR^{6b})N(R^{6e})(R^{6d})$, $-N(R^{6b})(R^{6e})$, $-OR^{6b}$, $-SR^{6b}$, $-S(O)R^{6b}$, $-S(O)_2R^{6b}$, $-S(NR^{6b})(NR^{6e})R^{6d}$, $-S(O)(NR^{6b})(R^{6e})$, $-S(O)_2N(R^{6b})(R^{6e})$, $-N(R^{6b})S(O)_2(R^{6e})$, $-P(R^{6b})(R^{6e})$, $-P(O)(R^{6b})(R^{6e})$, $-P(O)(OR^{6b})(R^{6e})$, $-P(O)(OR^{6b})(OR^{6e})$, C_{3-10} cycloalkyl, C_{1-6} alkyl-C_{3-10} cycloalkyl, C_{6-12} aryl, C_{1-6} alkyl-C_{6-12} aryl, heterocycloalkyl, C_{1-6} alkyl-(heterocycloalkyl), heteroaryl, or C_{1-6} alkyl-(heteroaryl), wherein the cycloalkyl, aryl, heterocycloalkyl, or heteroaryl

is each optionally substituted with 1 to 3 R^{6e}, the alkyl is optionally substituted with R^{6f}, and the alkynyl is optionally substituted with 1 to 4 R^{6j};

each R^{6b}, R^{6c} and R^{6d} is independently hydrogen, C_{1-6} alkyl, C_{1-6} hydroxyalkyl, C_{1-6} aminoalkyl, C_{2-6} alkoxyalkyl, C_{1-6} haloalkyl, C_{3-10} cycloalkyl, C_{1-6} alkyl-C_{3-10} cycloalkyl, C_{6-12} aryl, C_{1-6} alkyl-C_{6-12} aryl, heterocycloalkyl, C_{1-6} alkyl-(heterocycloalkyl), heteroaryl, or C_{1-6} alkyl-(heteroaryl), wherein the cycloalkyl, aryl, heterocycloalkyl, or heteroaryl is optionally substituted by 1 to 3 R^{6k};

each R^{6k} is independently C_{1-6} alkyl, C_{1-6} hydroxyalkyl, C_{1-6} aminoalkyl, C_{1-6} alkoxy, C_{2-6} alkoxyalkyl, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, C_{3-10} cycloalkyl, C_{1-6} alkyl-C_{3-10} cycloalkyl, heterocycloalkyl, or C_{1-6} alkyl-(heterocycloalkyl);

each R^{6e} is independently C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} hydroxyalkyl, C_{1-6} aminoalkyl, C_{1-6} alkoxy, C_{2-6} alkoxyalkyl, halogen, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, –CN, $-NO_2$, $-C(O)R^{6e1}$, $-C(O)OR^{6e1}$, $-OC(O)R^{6e1}$, $-C(O)N(R^{6e1})(R^{6e2})$, $-N(R^{6e1})C(O)R^{6e2}$, $-OC(O)N(R^{6e1})(R^{6e2})$, $-N(R^{6e1})C(O)OR^{6e2}$, $-C(=NR^{6e1})N(R^{6e2})(R^{6e3})$, $-N(R^{6e1})(R^{6e2})$, =O, $-OR^{6e1}$, $-SR^{6e1}$, $-S(O)R^{6e1}$, $-S(NR^{6e1})(NR^{6e2})$, $-S(O)(NR^{6e1})(R^{6e2})$, $-S(O)_2R^{6e1}$, $-S(O)_2N(R^{6e1})(R^{6e2})$, $-SF_5$, $-N(R^{6e1})S(O)_2(R^{6e2})$, $-P(R^{6e1})(R^{6e2})$, $-P(O)(R^{6e1})(R^{6e2})$, $-P(O)(OR^{6e1})(R^{6e2})$, $-P(O)(OR^{6e1})(OR^{6e2})$, $-Si(R^{6e1})(R^{6e2})(R^{6e3})$, C_{3-10} cycloalkyl, C_{1-6} alkyl-C_{3-10} cycloalkyl, C_{6-12} aryl, C_{1-6} alkyl-C_{6-12} aryl, heterocycloalkyl, C_{1-6} alkyl-heterocycloalkyl, heteroaryl, or C_{1-6} alkyl-heteroaryl, wherein the cycloalkyl, aryl, heterocycloalkyl, or heteroaryl is each optionally substituted with 1 to 3 R^{6h}, and the alkyl is optionally substituted with 1 to 3 R^{6m};

each R^{6e1}, R^{6e2}, and R^{6e3} is independently hydrogen, C_{1-6} alkyl, C_{1-6} hydroxyalkyl, C_{1-6} aminoalkyl, C_{1-6} alkoxyalkyl, C_{1-6} haloalkyl, C_{3-10} cycloalkyl, C_{1-6} alkyl-C_{3-10} cycloalkyl, C_{6-10} aryl, C_{1-6} alkyl-C_{6-10} aryl, heterocycloalkyl, C_{1-6} alkyl-(heterocycloalkyl), heteroaryl, or C_{1-6} alkyl-(heteroaryl), wherein the cycloalkyl, aryl, heterocycloalkyl, or heteroaryl is optionally substituted with 1 to 3 R^{6n};

each R^{6n} is C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} hydroxyalkyl, C_{1-6} aminoalkyl, C_{1-6} alkoxy, C_{2-6} alkoxyalkyl, halogen, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, –CN, $-C(O)R^{6n1}$, $-C(O)OR^{6n1}$, $-OC(O)R^{6n1}$, $-C(O)N(R^{6n1})(R^{6n2})$, $-N(R^{6n1})C(O)R^{6n2}$, $-OC(O)N(R^{6n1})(R^{6n2})$, $-N(R^{6n1})C(O)OR^{6n2}$, $-C(=NR^{6n1})N(R^{6n2})(R^{6n3})$, –

~~$N(R^{6n1})(R^{6n2})$, =O, —OH, $-SR^{6n1}$, $-S(O)R^{6n1}$, $-S(NR^{6n1})(NR^{6n2})R^{6n3}$, $-S(O)(NR^{6n1})(R^{6n2})$, $-S(O)_2R^{6n1}$, $-S(O)_2N(R^{6n1})(R^{6n2})$, or $-N(R^{6n1})S(O)_2(R^{6n2})$;~~

~~each R^{6n1}, R^{6n2} and R^{6n3} is independently hydrogen, C_{1-6} alkyl, C_{1-6} hydroxyalkyl, C_{1-6} aminoalkyl, C_{2-6} alkoxyalkyl, C_{1-6} haloalkyl, C_{3-10} cycloalkyl, C_{1-6} alkyl-C_{3-10} cycloalkyl, C_{6-10} aryl, C_{1-6} alkyl-C_{6-10} aryl, heterocycloalkyl, C_{1-6} alkyl-(heterocycloalkyl), heteroaryl, or C_{1-6} alkyl-(heteroaryl);~~

~~each R^{6h} is independently C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} hydroxyalkyl, C_{1-6} aminoalkyl, C_{1-6} alkoxy, C_{2-6} alkoxyalkyl, halogen, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, —CN, $-C(O)R^{6h1}$, $-C(O)OR^{6h1}$, $-OC(O)R^{6h1}$, $-C(O)N(R^{6h1})(R^{6h2})$, $-N(R^{6h1})C(O)R^{6h2}$, $-OC(O)N(R^{6h1})(R^{6h2})$, $-N(R^{6h1})C(O)OR^{6h2}$, $-C(=NR^{6h1})N(R^{6h2})(R^{6h3})$, $-N(R^{6h1})(R^{6h2})$, =O, —OH, $-SR^{6h1}$, $-S(O)R^{6h1}$, $-S(NR^{6h1})(NR^{6h2})R^{6h3}$, $-S(O)(NR^{6h1})(R^{6h2})$, $-S(O)_2R^{6h1}$, $-S(O)_2N(R^{6h1})(R^{6h2})$, $-N(R^{6h1})S(O)_2(R^{6h2})$, C_{3-10} cycloalkyl, C_{1-6} alkyl-C_{3-10} cycloalkyl, heterocycloalkyl, or C_{1-6} alkyl-(heterocycloalkyl);~~

~~each R^{6h1}, R^{6h2}, and R^{6h3} is independently hydrogen, C_{1-6} alkyl, C_{1-6} hydroxyalkyl, C_{1-6} aminoalkyl, C_{2-6} alkoxyalkyl, C_{1-6} haloalkyl, C_{3-10} cycloalkyl, C_{1-6} alkyl-C_{3-10} cycloalkyl, C_{6-10} aryl, C_{1-6} alkyl-C_{6-10} aryl, heterocycloalkyl, C_{1-6} alkyl-(heterocycloalkyl), heteroaryl, or C_{1-6} alkyl-(heteroaryl);~~

~~each R^{6m} is independently halogen, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, —CN, $-C(O)R^{6m1}$, $-C(O)OR^{6m1}$, $-OC(O)R^{6m1}$, $-C(O)N(R^{6m1})(R^{6m2})$, $-N(R^{6m3})C(O)R^{6m2}$, $-OC(O)N(R^{6m1})(R^{6m2})$, $-N(R^{6m1})C(O)OR^{6m2}$, $-C(=NR^{6m3})N(R^{6m1})(R^{6m2})$, $-N(R^{6m1})(R^{6m2})$, =O, —OH, $-SR^{6m1}$, $-S(O)R^{6m1}$, $-S(NR^{6m1})(NR^{6m2})R^{6m3}$, $-S(O)(NR^{6m1})(R^{6m2})$, $-S(O)_2R^{6m1}$, $-S(O)_2N(R^{6m1})(R^{6m2})$, or $-N(R^{6m3})S(O)_2(R^{6m2})$;~~

~~each R^{6m1}, R^{6m2}, and R^{6m3} is independently hydrogen, C_{1-6} alkyl, C_{1-6} hydroxyalkyl, C_{1-6} aminoalkyl, C_{2-6} alkoxyalkyl, C_{1-6} haloalkyl, C_{3-10} cycloalkyl, C_{1-6} alkyl-C_{3-10} cycloalkyl, C_{6-10} aryl, C_{1-6} alkyl-C_{6-10} aryl, heterocycloalkyl, C_{1-6} alkyl-(heterocycloalkyl), heteroaryl, or C_{1-6} alkyl-(heteroaryl);~~

~~R^{6f} is —OSi(R^{6f1})(R^{6f2})(R^{6f3});~~

~~R^{6f1}, R^{6f2}, and R^{6f3} are each independently C_{1-6} alkyl;~~

~~each R^{6j} is independently C_{2-6} alkoxyalkyl, halogen, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, —CN, $-C(O)R^{6j1}$, $-C(O)OR^{6j1}$, $-OC(O)R^{6j1}$, $-C(O)N(R^{6j1})(R^{6j2})$, $-N(R^{6j3})C(O)R^{6j2}$, $-$~~

~~$OC(O)N(R^{6j1})(R^{6j2})$, $-N(R^{6j1})C(O)OR^{6j2}$, $-C(=NR^{6j3})N(R^{6j1})(R^{6j2})$, $-N(R^{6j1})(R^{6j2})$, $=O$, $-OR^{6j1}$, $-SR^{6j1}$, $-S(O)R^{6j1}$, $-S(NR^{6j1})(NR^{6j2})$, $-S(NR^{6j1})(NR^{6j2})R^{6j3}$, $-S(O)(NR^{6j1})(R^{6j2})$, $-S(O)_2R^{6j1}$, $-S(O)_2N(R^{6j1})(R^{6j2})$, $-N(R^{6j1})S(O)_2(R^{6j2})$, $-Si(R^{6j1})(R^{6j2})(R^{6j3})$, C_{3-10} cycloalkyl, C_{6-12} aryl, heterocycloalkyl, or heteroaryl, wherein the cycloalkyl, aryl, heterocycloalkyl, or heteroaryl is optionally substituted with 1 to 3 R^{6p};~~

~~each R^{6j1}, R^{6j2}, and R^{6j3} is independently hydrogen, C_{1-6} alkyl, C_{1-6} hydroxyalkyl, C_{1-6} aminoalkyl, C_{2-6} alkoxyalkyl, C_{1-6} haloalkyl, C_{3-10} cycloalkyl, C_{1-6} alkyl-C_{3-10} cycloalkyl, C_{6-10} aryl, C_{1-6} alkyl-C_{6-10} aryl, heterocycloalkyl, C_{1-6} alkyl-(heterocycloalkyl), heteroaryl, or C_{1-6} alkyl-(heteroaryl);~~

~~each R^{6p} is independently C_{1-6} alkyl, C_{1-6} hydroxyalkyl, C_{1-6} aminoalkyl, C_{1-6} alkoxy, C_{2-6} alkoxyalkyl, halogen, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, $-CN$, $-C(O)R^{6p1}$, $-C(O)OR^{6p1}$, $-OC(O)R^{6p1}$, $-C(O)N(R^{6p1})(R^{6p2})$, $-N(R^{6p1})C(O)R^{6p2}$, $-OC(O)N(R^{6p1})(R^{6p2})$, $-N(R^{6p1})C(O)OR^{6p2}$, $-C(=NR^{6p3})N(R^{6p1})(R^{6p2})$, $-N(R^{6p1})(R^{6p2})$, $=O$, $-OH$, $-SR^{6p1}$, $-S(O)R^{6p1}$, $-S(NR^{6p1})(NR^{6p2})R^{6p3}$, $-S(O)(NR^{6p1})(R^{6p2})$, $-S(O)_2R^{6p1}$, $-S(O)_2N(R^{6p1})(R^{6p2})$, or $-N(R^{6p1})S(O)_2(R^{6p2})$;~~

~~each R^{6p1}, R^{6p2}, and R^{6p3} is independently hydrogen, C_{1-6} alkyl, C_{1-6} hydroxyalkyl, C_{1-6} aminoalkyl, C_{2-6} alkoxyalkyl, C_{1-6} haloalkyl, C_{3-10} cycloalkyl, C_{1-6} alkyl-C_{3-10} cycloalkyl, C_{6-10} aryl, C_{1-6} alkyl-C_{6-10} aryl, heterocycloalkyl, C_{1-6} alkyl-(heterocycloalkyl), heteroaryl, or C_{1-6} alkyl-(heteroaryl);~~

~~or R^5 and one R^{6a} together with the atoms to which they are attached form a heterocycloalkyl, optionally substituted with 1 to 3 R^{6g};~~

~~each R^{6g} is independently C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} hydroxyalkyl, C_{1-6} aminoalkyl, C_{2-6} alkoxyalkyl, halogen, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, or $-CN$;~~

~~R^7 is hydrogen, C_{1-6} alkyl, C_{1-6} hydroxyalkyl, C_{1-6} aminoalkyl, C_{1-6} alkoxy, C_{2-6} alkoxyalkyl, C_{1-6} alkylthio, halogen, C_{1-6} haloalkyl, $-CN$, $-OH$, $-NH_2$, C_{3-10} cycloalkyl, C_{1-6} alkyl-C_{3-10} cycloalkyl, heterocycloalkyl, or C_{1-6} alkyl-(heterocycloalkyl);~~

~~each heterocycloalkyl is a 3 to 20 membered ring having 1 to 4 heteroatoms each independently N, O or S; and~~

~~each heteroaryl is a 5 to 18 membered ring having 1 to 4 heteroatoms each independently N, O or S.~~